Cancer — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

197

Molecular (A)

100

Clinical (B–E)

Direct drugs

742

Via biomarker

472

Natural agents

Natural products

Merged ranked

1226

With trial/literature evidence

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, ChEMBL, DGIdb, OSMF Chronic Disease Review, PubMed MeSH · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery

Best-intervention remission

NSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS 16-19 months with osimertinib (FLAURA2 combination up to 25 months); immunotherapy (pembrolizumab): 5-year OS ~31% in high PD-L1 expressers vs ~16% chemotherapy; SBRT for early-stage inoperable: 80-90% local control at 3 years

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations

Primary barrier

access/practice

Barrier detail: Biomarker testing (PD-L1, EGFR/ALK/ROS1 mutations) still not universal; only 5-6% of high-risk smokers undergo low-dose CT screening despite 20% mortality reduction (NLST trial); smoking cessation dramatically reduces incidence but is underfunded

Last SoC change: 2023 — osimertinib adjuvant ADAURA (Stage IB-IIIA EGFR+ NSCLC) standard of care; neoadjuvant chemo-immunotherapy (CheckMate 816) plus surgery now standard for resectable stage III; PD-1/PD-L1 inhibitors first-line since 2016-2018; targeted therapy since 2010 (erlotinib)

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004992 · EFO: EFO_0000311 · MESH: D009369 · UMLS_CUI: C0006826

Alterations

197 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal bleeding	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal granulocytopoietic cell morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Adrenocortical carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Aganglionic megacolon	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Amblyopia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Aniridia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Breast carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cataract	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cervix cancer	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Choroid plexus carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic myelogenous leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Colon cancer	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Colonic diverticula	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Constipation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Deeply set eye	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Diarrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Disproportionate tall stature	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dysgerminoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Eczematoid dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Elevated circulating calcitonin concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Elevated urinary epinephrine level	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Embryonal rhabdomyosarcoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Endometrial carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Erythema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Esophageal carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Failure to thrive in infancy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Flushing	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ganglioneuroma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Generalized hypotonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Glaucoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Global developmental delay	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hereditary nonpolyposis colorectal carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
High palate	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
High, narrow palate	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperlordosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypotonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased total eosinophil count	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Iris coloboma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Joint hypermobility	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Juvenile myelomonocytic leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Kyphosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Large forehead	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lens subluxation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Leukocoria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphadenopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malignant eosinophil proliferation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malignant mesothelioma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Medullary thyroid carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Medulloblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myelofibrosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myeloproliferative disorder	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the pancreas	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephroblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nodular goiter	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nystagmus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Optic atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Osteoporosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Osteosarcoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ovarian neoplasm	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ovarian papillary adenocarcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Papillary renal cell carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Papillary thyroid carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Parathyroid hyperplasia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pectus excavatum	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pes cavus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pheochromocytoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pleuropulmonary blastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Prostate cancer	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Proximal femoral epiphysiolysis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pruritus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Psoriasiform dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Reduced leukocyte alkaline phosphatase	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Reduced visual acuity	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Renal cell carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Retinal calcification	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Retinoblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Rhabdomyosarcoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Scoliosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Skin plaque	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Spontaneous, recurrent epistaxis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Synovial sarcoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thick eyebrow	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thick lower lip vermilion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thrombocytopenia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Transient myeloproliferative syndrome	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AKT1 AKT serine/threonine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AMER1 APC membrane recruitment protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APC APC regulator of Wnt signaling pathway	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASXL1 ASXL transcriptional regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AXIN1 axin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BAP1 BRCA1 associated deubiquitinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BARD1 BRCA1 associated RING domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCR BCR activator of RhoGEF and GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA1 BRCA1 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRIP1 BRCA1 interacting DNA helicase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CBL Cbl proto-oncogene	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCND1 cyclin D1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDC73 cell division cycle 73	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH1 cadherin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK4 cyclin dependent kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CEBPA CCAAT enhancer binding protein alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CREBBP CREB binding lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DICER1 dicer 1, ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNMT3A DNA methyltransferase 3 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Duration of response (RECIST 1.1, as modified by PCWG3)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EML4 EMAP like 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EP300 EP300 lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB2 erb-b2 receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB3 erb-b2 receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETV6 ETS variant transcription factor 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EXT1 exostosin glycosyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXO11 F-box protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXW7 F-box and WD repeat domain containing 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR1 fibroblast growth factor receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR3 fibroblast growth factor receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR4 fibroblast growth factor receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLCN folliculin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT3 fms related receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA2 GATA binding protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRAS HRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IDH1 isocitrate dehydrogenase (NADP(+)) 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IDH2 isocitrate dehydrogenase (NADP(+)) 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP2K1 mitogen-activated protein kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K1 mitogen-activated protein kinase kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MET MET proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLH1 mutL homolog 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MPL MPL proto-oncogene, thrombopoietin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH2 mutS homolog 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH6 mutS homolog 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MUTYH mutY DNA glycosylase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Median Standardized Uptake Value (SUV)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
NBN nibrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NF1 neurofibromin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH1 notch receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NPM1 nucleophosmin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRAS NRAS proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRG1 neuregulin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK1 neurotrophic receptor tyrosine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Objective Response Rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Overall Response Rate (ORR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Overall survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PALB2 partner and localizer of BRCA2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRA platelet derived growth factor receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PMS2 PMS1 homolog 2, mismatch repair system component	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE DNA polymerase epsilon, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTCH1 patched 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTEN phosphatase and tensin homolog	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPN11 protein tyrosine phosphatase non-receptor type 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Progression-free Survival (PFS)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
RAD51C RAD51 paralog C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAD51D RAD51 paralog D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAF1 Raf-1 proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RB1 RB transcriptional corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RET ret proto-oncogene	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ROS1 ROS proto-oncogene 1, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RUNX1 RUNX family transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDHA succinate dehydrogenase complex flavoprotein subunit A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SETBP1 SET binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMAD4 SMAD family member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMARCB1 SWI/SNF related BAF chromatin remodeling complex subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SRC SRC proto-oncogene, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SRSF2 serine and arginine rich splicing factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
STK11 serine/threonine kinase 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TERT telomerase reverse transcriptase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TET2 tet methylcytosine dioxygenase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TGFBR2 transforming growth factor beta receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TP53 tumor protein p53	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Time to progression	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Time to response	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
WRN WRN RecQ like helicase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
WT1 WT1 transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

From opensourcemed.info/chronic-disease — Cancer metabolism as a therapeutic target and review of interventions. Candidates for further study, not approved treatments.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Price (UK / US)	Trials & literature	Sources	Links
BICALUTAMIDE	Small molecule	Approved	Strong	110	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 8 Cochrane 6 Meta-analysis 191 Trial pubs 138 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00026377 — SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (COMPLETED) PHASE1 NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04563936 — Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (COMPLETED) PHASE3 NCT02376296 — Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients (COMPLETED) NCT02678520 — Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients (WITHDRAWN) PHASE2 NCT00349557 — Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer (COMPLETED) PHASE2 NCT02454543 — Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (ACTIVE_NOT_RECRUITING) NA Published literature Cochrane review The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis (Frontiers in endocrinology, 2023) Cochrane review Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis (JAMA network open, 2020) Cochrane review Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis (American journal of clinical oncology, 2020) Cochrane review First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials (BJU international, 2017) Cochrane review Gynecomastia in Patients with Prostate Cancer: A Systematic Review (PloS one, 2015) Meta-analysis Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials (Journal of endocrinological investigation, 2025) Meta-analysis Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma (Journal of gynecologic oncology, 2021) Systematic review Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review (ESMO open, 2024) Systematic review Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review (Journal of geriatric oncology, 2021) Clinical trial publication Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809) (The Prostate, 2026) Clinical trial publication Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy (International journal of radiation oncology, biology, physics, 2025) Clinical trial publication Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy (The Prostate, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	110	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 13 Cochrane 16 Meta-analysis 166 Trial pubs 53 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00337545 — Phase II Trial of RAD001 in Refractory Colorectal Cancer (COMPLETED) PHASE2 NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT05476939 — Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (RECRUITING) PHASE3 NCT00516412 — Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (COMPLETED) PHASE2 NCT06482086 — Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer (RECRUITING) PHASE2 NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT01334502 — Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (COMPLETED) PHASE1 Published literature Cochrane review Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (International journal of dermatology, 2026) Cochrane review [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review] (Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2025) Cochrane review mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis (Clinical transplantation, 2022) Cochrane review Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review (Journal of pediatric orthopedics. Part B, 2022) Cochrane review Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022) Meta-analysis Impact of Modern Strategies for Graft-Versus-Host Disease Prophylaxis on Relapse Risk in Matched-Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis of Randomized Trials (European journal of haematology, 2026) Meta-analysis mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis (BMJ open, 2021) Systematic review Impact of immunosuppressive therapy on non-melanoma skin cancer after solid organ transplantation: A critical systematic review (Transplant immunology, 2026) Systematic review Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates (Pediatric research, 2025) Systematic review Topical sirolimus in dermatology: a systematic review (Clinical and experimental dermatology, 2024) Clinical trial publication Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial (The Lancet. Haematology, 2026) Clinical trial publication Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS (Blood, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 289 Cochrane 479 Meta-analysis 2345 Trial pubs 1085 RCT View evidence Registry trials NCT01492673 — Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma (COMPLETED) PHASE2 NCT00755157 — Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer (WITHDRAWN) PHASE2 NCT00952029 — Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer (COMPLETED) PHASE2, PHASE3 NCT07117877 — Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer (NOT_YET_RECRUITING) PHASE2 NCT07637851 — Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT00015951 — Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers (COMPLETED) PHASE2 NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT05476939 — Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (RECRUITING) PHASE3 Published literature Cochrane review First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety (Frontiers in immunology, 2026) Cochrane review Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis (BMC cancer, 2026) Cochrane review Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis (Brain and behavior, 2026) Cochrane review The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network Meta-Analysis of Antiangiogenic Combination Therapies (Cancer medicine, 2026) Cochrane review A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma (Asian Pacific journal of cancer prevention : APJCP, 2026) Meta-analysis Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model (Health technology assessment (Winchester, England), 2026) Meta-analysis First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression (Critical reviews in oncology/hematology, 2026) Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy (Frontiers in immunology, 2026) Clinical trial publication Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma (Technology in cancer research & treatment, 2026) Clinical trial publication Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study (Cancer communications (London, England), 2026) Clinical trial publication Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CAPECITABINE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 86 Cochrane 151 Meta-analysis 2135 Trial pubs 857 RCT View evidence Registry trials NCT00459901 — Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer (TERMINATED) PHASE2 NCT01711242 — Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma (COMPLETED) PHASE2 NCT02854072 — A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients (UNKNOWN) PHASE3 NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT02947061 — S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT07268677 — A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. (NOT_YET_RECRUITING) PHASE2 NCT03167177 — QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (WITHDRAWN) PHASE1, PHASE2 NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (NOT_YET_RECRUITING) PHASE2 Published literature Cochrane review Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis (Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2026) Cochrane review First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis (JAMA network open, 2026) Cochrane review Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis (JAMA dermatology, 2026) Cochrane review Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Cochrane review Hand-foot syndrome prevention: pharmacological interventions-systematic review and network meta-analysis (BMJ supportive & palliative care, 2026) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis (Bulletin du cancer, 2026) Systematic review Evaluating adherence to literature-derived systemic therapy standards for resectable intrahepatic cholangiocarcinoma: A systematic review and cohort study (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2026) Systematic review Tumor Lysis Syndrome in Colorectal Cancer-A Systematic Review of Literature (Journal of gastrointestinal cancer, 2026) Systematic review Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions (Endocrine, 2026) Clinical trial publication Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial (The lancet. Gastroenterology & hepatology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL411	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 29 Cochrane 39 Meta-analysis 189 Trial pubs 64 RCT View evidence Registry trials NCT06140836 — A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (ACTIVE_NOT_RECRUITING) PHASE3 NCT02074878 — CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (TERMINATED) PHASE1 NCT02568267 — Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (ACTIVE_NOT_RECRUITING) PHASE2 NCT02336451 — A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (COMPLETED) PHASE2 NCT00939770 — Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (COMPLETED) PHASE1, PHASE2 NCT03947385 — Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (RECRUITING) PHASE1, PHASE2 NCT01744652 — Dasatinib and Crizotinib in Advanced Cancer (COMPLETED) PHASE1 NCT05384626 — A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis (BMC cancer, 2026) Cochrane review Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review (BMC cancer, 2026) Cochrane review Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network (British journal of cancer, 2025) Cochrane review Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review (Expert opinion on pharmacotherapy, 2025) Cochrane review Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis (BMJ open, 2024) Meta-analysis A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer (Anticancer research, 2026) Meta-analysis Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025) Meta-analysis Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis (Future oncology (London, England), 2025) Systematic review Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review (Cells, 2026) Clinical trial publication Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan (Cancer science, 2026) Clinical trial publication Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial (Future oncology (London, England), 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DECITABINE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 11 Cochrane 28 Meta-analysis 229 Trial pubs 62 RCT View evidence Registry trials NCT01893372 — Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS) (COMPLETED) PHASE2 NCT00740181 — Decitabine, Cytarabine, GCSF for Refractory AML/MDS (TERMINATED) PHASE2 NCT02412475 — Epigenetic Reprogramming in Relapse AML (TERMINATED) PHASE1 NCT00867672 — Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia (COMPLETED) PHASE2 NCT00085293 — Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (COMPLETED) PHASE2 NCT04485052 — Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (SUSPENDED) PHASE1, PHASE2 NCT03613532 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (ACTIVE_NOT_RECRUITING) PHASE1 NCT05829226 — A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) (COMPLETED) PHASE1 Published literature Cochrane review Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm (Cancer, 2026) Cochrane review The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis (Clinical and experimental medicine, 2025) Cochrane review Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis (Medicine, 2022) Cochrane review Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis (PloS one, 2022) Cochrane review Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis (Acta oncologica (Stockholm, Sweden), 2021) Meta-analysis Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials (Annals of hematology, 2026) Meta-analysis Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis (Blood advances, 2026) Meta-analysis The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis (Annals of hematology, 2025) Meta-analysis Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes (Annals of hematology, 2025) Systematic review Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review (Annals of hematology, 2026) Clinical trial publication All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia (The New England journal of medicine, 2026) Clinical trial publication [Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia] (Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DOCETAXEL	Small molecule	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 165 Cochrane 296 Meta-analysis 4011 Trial pubs 1668 RCT View evidence Registry trials NCT03228186 — Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (TERMINATED) PHASE2 NCT00155883 — Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer (TERMINATED) PHASE2 NCT05005728 — XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (COMPLETED) PHASE2 NCT00755157 — Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer (WITHDRAWN) PHASE2 NCT02947061 — S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT03517969 — M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00073866 — Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer (COMPLETED) PHASE1, PHASE2 NCT03873272 — The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL (COMPLETED) NA Published literature Cochrane review Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making (Expert review of clinical pharmacology, 2026) Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025 (Frontiers in endocrinology, 2026) Cochrane review Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Scientific reports, 2025) Meta-analysis PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes (Cancer treatment reviews, 2026) Meta-analysis Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis (Clinical genitourinary cancer, 2026) Meta-analysis Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations (CPT: pharmacometrics & systems pharmacology, 2026) Meta-analysis Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis (Future oncology (London, England), 2026) Meta-analysis Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer (Journal of comparative effectiveness research, 2026) Systematic review Systematic review on effectiveness of flavonoids against breast cancer: insights from in-vitro, in-vivo studies and molecular pathway studies (Drug development and industrial pharmacy, 2026) Systematic review Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review (Frontiers in immunology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 37 Cochrane 76 Meta-analysis 1874 Trial pubs 923 RCT View evidence Registry trials NCT02288741 — Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (COMPLETED) PHASE3 NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL (RECRUITING) PHASE1, PHASE2 NCT05535998 — TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT (COMPLETED) NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT00966706 — Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer (COMPLETED) PHASE2 NCT01094964 — Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer (UNKNOWN) PHASE3 Published literature Cochrane review Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group (Actas urologicas espanolas, 2026) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials (PloS one, 2024) Meta-analysis The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis (Urologic oncology, 2023) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Systematic review An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis (Molecular aspects of medicine, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 17 Cochrane 24 Meta-analysis 180 Trial pubs 119 RCT View evidence Registry trials NCT05913427 — Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) (RECRUITING) PHASE2 NCT07462663 — SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer (NOT_YET_RECRUITING) PHASE4 NCT06963593 — Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy (NOT_YET_RECRUITING) PHASE4 NCT04046185 — Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer (UNKNOWN) EARLY_PHASE1 NCT03283488 — Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. (COMPLETED) PHASE2 NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer (NOT_YET_RECRUITING) PHASE2 NCT02980653 — Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT (UNKNOWN) PHASE2 NCT00002465 — High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature (The journal of nutrition, health & aging, 2024) Cochrane review Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review (Journal of gynecologic oncology, 2023) Cochrane review The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis (BJOG : an international journal of obstetrics and gynaecology, 2023) Cochrane review Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review (BioMed research international, 2022) Cochrane review Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review (Palliative medicine, 2022) Meta-analysis Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis (Journal of cachexia, sarcopenia and muscle, 2024) Meta-analysis The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials (Journal of gynecology obstetrics and human reproduction, 2021) Systematic review Pharmacological Treatments for Cancer-Related Anorexia-Cachexia Syndrome: An Umbrella Review of Systematic Reviews and Meta-Analyses (Nutrition and cancer, 2026) Clinical trial publication Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial (Gynecologic oncology, 2025) Clinical trial publication [Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study] (Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024) Clinical trial publication Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors (ESMO open, 2024) Clinical trial publication Prophylactic Versus Reactive Megestrol Acetate Use for Critical Body Weight Loss in Patients with Pharyngeal and Laryngeal Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy (Nutrition and cancer, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NIVOLUMAB	Biologic	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 187 Cochrane 357 Meta-analysis 1069 Trial pubs 431 RCT View evidence Registry trials NCT06715241 — A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS (ACTIVE_NOT_RECRUITING) PHASE2 NCT03631641 — Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy (TERMINATED) PHASE2 NCT01024231 — Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (COMPLETED) PHASE1 NCT03991130 — High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma (TERMINATED) PHASE2 NCT02538666 — An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (COMPLETED) PHASE3 NCT03371381 — An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung (TERMINATED) PHASE1, PHASE2 NCT07100405 — TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment (RECRUITING) NCT03167177 — QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (WITHDRAWN) PHASE1, PHASE2 Published literature Cochrane review Diagnosis and management of immune checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026) Cochrane review Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis (Frontiers in immunology, 2026) Cochrane review Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (Clinical lung cancer, 2026) Cochrane review First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety (Frontiers in immunology, 2026) Cochrane review Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials (BMC cancer, 2026) Meta-analysis Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis (Hematological oncology, 2026) Clinical trial publication Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma (Journal for immunotherapy of cancer, 2026) Clinical trial publication Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial (Journal for immunotherapy of cancer, 2026) Clinical trial publication CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma (Clinical lung cancer, 2026) Clinical trial publication Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study (European journal of cancer (Oxford, England : 1990), 2026) Clinical trial publication A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI) (Clinical lung cancer, 2026) Randomized controlled trial Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 (Nature, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
OLAPARIB	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 29 Cochrane 53 Meta-analysis 297 Trial pubs 141 RCT View evidence Registry trials NCT05005728 — XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (COMPLETED) PHASE2 NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT07637851 — Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT03057145 — Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT07018622 — Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (RECRUITING) PHASE2 NCT02430311 — The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. (COMPLETED) PHASE1 NCT03784014 — Molecular Profiling of Advanced Soft-tissue Sarcomas (COMPLETED) PHASE3 NCT06607692 — Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review (International journal of molecular sciences, 2025) Cochrane review Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies (European urology focus, 2026) Cochrane review PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis (JAMA network open, 2025) Cochrane review Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis (Asian Pacific journal of cancer prevention : APJCP, 2025) Cochrane review Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis (European journal of obstetrics, gynecology, and reproductive biology, 2025) Meta-analysis Effectiveness and safety of PARP inhibitors in ovarian cancer: An umbrella review of systematic reviews and meta-analyses (Critical reviews in oncology/hematology, 2025) Meta-analysis A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis (Journal of ovarian research, 2025) Meta-analysis Efficacy and safety of PARP inhibitors in prostate cancer: An umbrella review of systematic reviews and meta-analyses (Critical reviews in oncology/hematology, 2025) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib (Cancer, 2026) Clinical trial publication Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial (World journal of urology, 2026) Clinical trial publication Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial (JCO precision oncology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PACLITAXEL	Small molecule	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 189 Cochrane 264 Meta-analysis 5654 Trial pubs 2057 RCT View evidence Registry trials NCT06370754 — Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00019812 — Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 (COMPLETED) PHASE2 NCT01264328 — Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (COMPLETED) PHASE2 NCT00003957 — Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT06965829 — The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC (NOT_YET_RECRUITING) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA Published literature Cochrane review Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung Cancer: A Single-arm Meta-analysis (Anticancer research, 2026) Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Systematic review and first meta-analysis of the efficacy and safety of gemcitabine-cisplatin combined with paclitaxel in patients with advanced biliary tract cancer (European journal of clinical pharmacology, 2026) Cochrane review Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis (Frontiers in immunology, 2026) Cochrane review Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis (Annals of medicine, 2026) Meta-analysis Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study (Frontiers in immunology, 2026) Systematic review Dual TP53 mutations in ovarian high-grade serous carcinoma combined with squamous cell carcinoma: a case report and systematic literature review (Journal of ovarian research, 2026) Systematic review Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review (Cells, 2026) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study (Cancer communications (London, England), 2026) Clinical trial publication Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study (Signal transduction and targeted therapy, 2026) Clinical trial publication Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 16 Cochrane 18 Meta-analysis 88 Trial pubs 36 RCT View evidence Registry trials NCT03923036 — Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer (UNKNOWN) NCT04252456 — Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status (UNKNOWN) NA NCT00729157 — Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (COMPLETED) PHASE2 NCT01889680 — Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (WITHDRAWN) PHASE2 NCT04392479 — TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (UNKNOWN) PHASE3 NCT00601991 — A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia (WITHDRAWN) PHASE2 NCT06047379 — Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (RECRUITING) PHASE1, PHASE2 NCT00896662 — Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 (COMPLETED) Published literature Cochrane review Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis (Hypertension research : official journal of the Japanese Society of Hypertension, 2026) Cochrane review Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment (Annals of palliative medicine, 2024) Cochrane review Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis (Medicine, 2023) Cochrane review A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety (Critical reviews in oncology/hematology, 2023) Cochrane review Recent advances in the molecular targeted drugs for prostate cancer (International urology and nephrology, 2023) Meta-analysis Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials (Journal of clinical pharmacy and therapeutics, 2022) Meta-analysis The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis (Cancer treatment and research communications, 2021) Systematic review Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review (Molecular diagnosis & therapy, 2021) Clinical trial publication Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629) (European journal of cancer (Oxford, England : 1990), 2026) Clinical trial publication Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients (European journal of clinical investigation, 2026) Clinical trial publication A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer (International journal of clinical oncology, 2025) Clinical trial publication Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial (ESMO open, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AXITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
AZACITIDINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CARFILZOMIB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CELECOXIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CERITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CETUXIMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1129	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200374	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200598	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201112	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201477	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201506	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201746	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237054	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1455	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742992	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742994	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1743047	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908391	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1977579	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2105737	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2216870	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL238071	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL24828	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL3137342	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL313972	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL408513	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL452231	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL488	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL513	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL691	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL705	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL717	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL727	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CLOFARABINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CYTARABINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DENILEUKIN DIFTITOX	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 3 Cochrane 3 Meta-analysis 34 Trial pubs 4 RCT View evidence Registry trials NCT00945269 — Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (TERMINATED) PHASE1, PHASE2 NCT00493129 — Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) (COMPLETED) PHASE2 NCT00726037 — A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer (TERMINATED) PHASE2 NCT00278369 — Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer (COMPLETED) EARLY_PHASE1 NCT00003615 — Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT00880360 — A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (COMPLETED) PHASE2 NCT00051012 — Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients (COMPLETED) PHASE4 NCT00513188 — Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma (WITHDRAWN) NA Published literature Cochrane review Interventions for mycosis fungoides (The Cochrane database of systematic reviews, 2020) Cochrane review Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review (The British journal of dermatology, 2014) Cochrane review Interventions for mycosis fungoides (The Cochrane database of systematic reviews, 2012) Meta-analysis Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma (American journal of hematology, 2011) Clinical trial publication Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025) Clinical trial publication Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer (Gynecologic oncology, 2024) Clinical trial publication Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (Cancer science, 2021) Clinical trial publication Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control (Journal of immunotherapy (Hagerstown, Md. : 1997), 2019) Clinical trial publication E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study (Cancer science, 2018) Randomized controlled trial Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies (Clinical lymphoma, myeloma & leukemia, 2013) Randomized controlled trial Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Randomized controlled trial Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK) (Clinical lymphoma, 2002) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FILGRASTIM	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUDARABINE PHOSPHATE	Small molecule	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUTAMIDE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GEFITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GOSERELIN	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
HISTRELIN	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBRUTINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IPILIMUMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IXABEPILONE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 2 Cochrane 5 Meta-analysis 99 Trial pubs 33 RCT View evidence Registry trials NCT00025194 — Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer (COMPLETED) PHASE1, PHASE2 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT01079793 — Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery (WITHDRAWN) PHASE1, PHASE2 NCT00020371 — BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy (COMPLETED) PHASE1 NCT00022542 — BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma (TERMINATED) PHASE2 NCT00182702 — Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (COMPLETED) PHASE2 NCT00207090 — Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer (COMPLETED) PHASE1 NCT00789581 — A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (COMPLETED) PHASE3 Published literature Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer (Future oncology (London, England), 2010) Meta-analysis Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer (Future oncology (London, England), 2024) Meta-analysis Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis (Medicine, 2016) Meta-analysis Systematic review of ixabepilone for treating metastatic breast cancer (Breast cancer (Tokyo, Japan), 2017) Meta-analysis Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data (The Lancet. Oncology, 2007) Systematic review Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective (Clinical breast cancer, 2016) Clinical trial publication Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial (JAMA oncology, 2022) Clinical trial publication Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (British journal of cancer, 2022) Clinical trial publication A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer (Clinical breast cancer, 2021) Clinical trial publication UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer (European journal of cancer (Oxford, England : 1990), 2018) Clinical trial publication A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance) (Clinical pharmacology and therapeutics, 2019) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MITOMYCIN	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
NICOTINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
NILUTAMIDE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBINUTUZUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
PANITUMUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 41 Cochrane 84 Meta-analysis 275 Trial pubs 136 RCT View evidence Registry trials NCT01264328 — Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (COMPLETED) PHASE2 NCT01017653 — Panitumumab and Irinotecan for Malignant Gliomas (TERMINATED) PHASE2 NCT03231722 — First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (COMPLETED) PHASE3 NCT01130701 — A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . . (WITHDRAWN) PHASE2 NCT07543744 — A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI (RECRUITING) PHASE1 NCT05121038 — CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT01312493 — Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab (WITHDRAWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 Published literature Cochrane review Outcomes of Epidermal Growth Factor Receptor Inhibitors in Locally Advanced and Metastatic Anal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (Journal of gastrointestinal cancer, 2026) Cochrane review First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis (JAMA network open, 2026) Cochrane review The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis (European journal of pharmacology, 2025) Cochrane review Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT (PloS one, 2024) Cochrane review The Use of Fluorescent Markers to Detect and Delineate Head and Neck Cancer: A Scoping Review (Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2025) Meta-analysis Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis (Critical reviews in oncology/hematology, 2026) Meta-analysis First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group) (European journal of cancer (Oxford, England : 1990), 2026) Meta-analysis Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: A meta-analysis of survival outcomes in resectable and unresectable settings (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2026) Systematic review Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research (Clinical and translational medicine, 2026) Systematic review A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science (Cancer investigation, 2026) Clinical trial publication Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026) Clinical trial publication Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PENTOSTATIN	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
PERTUZUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
REGORAFENIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
RESVERATROL Repurposing	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb, OSMF Chronic Disease Review	—
RITUXIMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TEMSIROLIMUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRASTUZUMAB EMTANSINE	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VISMODEGIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VORINOSTAT	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BENORILATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BRIGATINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BUSULFAN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BUTAMBEN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCIFEDIOL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCIPOTRIENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCITRIOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CANRENONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAPIVASERTIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CARFILZOMIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CEFONICID SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CEFPODOXIME PROXETIL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CEMIPLIMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CERITINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CERIVASTATIN SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHENODEOXYCHOLIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORDIAZEPOXIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORHEXIDINE GLUCONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORMADINONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHLOROTRIANISENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLOROXINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORPROMAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHOLECALCIFEROL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CICLESONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
CLASCOTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOBETASOL PROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOCORTOLONE PIVALATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CLOFARABINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CLOTRIMAZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CODEINE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
COLCHICINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CROMOLYN SODIUM Repurposing	Small molecule	Approved	Strong	95	UK £10–£20 / inhaler or amps · US $15–$30 / supply	—	DGIdb	ChEMBL Open Targets
CYCLANDELATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
CYPROTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CYTARABINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DACTINOMYCIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DANAZOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DAROLUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DAUNORUBICIN LIPOSOMAL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DECITABINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DEFERASIROX Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DEFLAZACORT Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESERPIDINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESLANOSIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOGESTREL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOXIMETASONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOXYCORTICOSTERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DESOXYCORTICOSTERONE PIVALATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIDANOSINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIETHYLCARBAMAZINE CITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIFLORASONE DIACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIFLUPREDNATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIGITOXIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIGOXIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIPHENOXYLATE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DOFETILIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
DROMOSTANOLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DRONEDARONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DROSPIRENONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DURVALUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DUTASTERIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DYCLONINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DYDROGESTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ECONAZOLE NITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
EFAVIRENZ Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EFLORNITHINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENSARTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENTRECTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENZALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EPIGALLOCATECHIN GALLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ERGOCALCIFEROL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ERLOTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL 3-BENZOATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL CYPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL VALERATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRAMUSTINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRAMUSTINE PHOSPHATE SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ESTRIOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHACRYNIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHINYL ESTRADIOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ETHYLESTRENOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHYNODIOL DIACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETONOGESTREL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETOPOSIDE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
EVEROLIMUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EXEMESTANE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EXIFONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FEBUXOSTAT Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENRETINIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENTANYL CITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FEPRAZONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FILGOTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FINASTERIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUCYTOSINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUDARABINE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
FLUDROCORTISONE Repurposing	Small molecule	Approved	Strong	95	UK £6–£10 / 30 tabs (0.1mg) · US $6 / 30 tabs (0.1mg, Cost Plus)	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FLUNISOLIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOCINOLONE ACETONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOCINONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOROMETHOLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOROURACIL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FLUOXYMESTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUPREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
FLURANDRENOLIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUSPIRILENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FULVESTRANT Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GEFITINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GEMCITABINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GENTIAN VIOLET CATION Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GESTODENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GILTERITINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GLUTATHIONE DISULFIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GLYCYRRHIZIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GRISEOFULVIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALCINONIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALOBETASOL PROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HALOPERIDOL DECANOATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALOPROGIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HEXACHLOROPHENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HYDROCORTISONE BUTYRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE PROBUTATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE VALERATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IBRUTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IBUPROFEN, SODIUM SALT Repurposing	Small molecule	Approved	Strong	95	UK Very low cost OTC/prescription · US Very low cost	—	DGIdb	—
IDARUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
IDEBENONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IFOSFAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IMATINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IMATINIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INDINAVIR SULFATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IOPAMIDOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IPILIMUMAB Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
ISOPROPYL UNOPROSTONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ISOTRETINOIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IXAZOMIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LACTATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LEUPROLIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LIOTHYRONINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOPERAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LORACARBEF Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
LORATADINE Repurposing	Small molecule	Approved	Strong	95	UK £1–£2 / 30 tabs · US $3–$6 / 30 tabs	—	DGIdb	—
LORLATINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOTEPREDNOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOVASTATIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LULICONAZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MAPROTILINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MASOPROCOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEDRYSONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEGESTROL ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MELOXICAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MELPHALAN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEPHOBARBITAL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEPREDNISONE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	DGIdb	ChEMBL Open Targets
MESTRANOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs	—	DGIdb	ChEMBL Open Targets
METHANDROSTENOLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
METHYLENE BLUE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
METHYLPREDNISOLONE ACETATE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
METHYLTESTOSTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METIPRANOLOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MIDAZOLAM HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MIFEPRISTONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MILTEFOSINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MINOCYCLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MITOMYCIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MITOTANE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
MOCLOBEMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MOMETASONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MORICIZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MYCOPHENOLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MYCOPHENOLATE MOFETIL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
NANDROLONE DECANOATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NANDROLONE PHENPROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NEFAZODONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NELFINAVIR Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NICARDIPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NICARDIPINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NICLOSAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIFEDIPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NILOTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NILOTINIB HYDROCHLORIDE MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NILUTAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NINTEDANIB ESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIRAPARIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIROGACESTAT Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NISOLDIPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NITAZOXANIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NITROFURAZONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIVOLUMAB Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
NORELGESTROMIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORETHINDRONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NORETHYNODREL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
NORGESTIMATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORGESTREL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORTRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
O-PHENANTHROLINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OCTOCRYLENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OMACETAXINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OMACETAXINE MEPESUCCINATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OSIMERTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXALIPLATIN Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
OXANDROLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXAZEPAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXYMETHOLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXYPHENISATIN ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PACLITAXEL PROTEIN-BOUND Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
PALBOCICLIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PARAMETHASONE ACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE Repurposing	Small molecule	Approved	Strong	95	UK £2–£4 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
PAZOPANIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PEMBROLIZUMAB Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
PEMETREXED DISODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PENTAMIDINE ISETHIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PERHEXILINE MALEATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PERMETHRIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PHENELZINE SULFATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PHENFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	UK £3–£8 / supply · US $6–$15 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
PIMOZIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PITAVASTATIN CALCIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PODOFILOX Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PONATINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PONATINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PRASTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PRAZEPAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs	—	ChEMBL	ChEMBL Open Targets
PREDNICARBATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
PREDNISOLONE ACETATE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
PREDNISONE Repurposing	Small molecule	Approved	Strong	95	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	DGIdb	—
PRIMIDONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROBENECID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROGESTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROMAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PYRIDOSTIGMINE BROMIDE Repurposing	Small molecule	Approved	Strong	95	UK £15–£25 / 60 tabs · US $20–$35 / 30–60 tabs	—	DGIdb	ChEMBL Open Targets
PYRIMETHAMINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PYRITHIONE ZINC Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PYRVINIUM PAMOATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
QUININE SULFATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RABEPRAZOLE SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RAMUCIRUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REGORAFENIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REPAGLINIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REPOTRECTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RESERPINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIBOCICLIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIFAMPIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIFAMYCIN SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RIFAPENTINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIMONABANT Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ROCURONIUM BROMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RUCAPARIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SALMETEROL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SAQUINAVIR MESYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SERTINDOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SERTRALINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $4–$9 / 30 tabs	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $4–$10 / 30–90 tabs	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SORAFENIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SOTALOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SPARFLOXACIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SPIRONOLACTONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
STANOZOLOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
SULFACARBAMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SULFISOXAZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SULINDAC Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TALAZOPARIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TALETRECTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TAMOXIFEN CITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TANNIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM SODIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TELITHROMYCIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TEMOZOLOMIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TEPOTINIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOLACTONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE CYPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE ENANTHATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE PROPIONATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
THIOGUANINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
THIOTEPA Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TIOCONAZOLE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOLVAPTAN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TOREMIFENE CITRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRASTUZUMAB Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
TREMELIMUMAB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIAMCINOLONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIAMCINOLONE DIACETATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRIAMTERENE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIBROMSALAN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRICLOSAN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIFLUOPERAZINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRILOSTANE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIPARANOL Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
UMBRALISIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VALPROIC ACID Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VALRUBICIN Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VEMURAFENIB Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VENETOCLAX Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINBLASTINE SULFATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINCRISTINE SULFATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINORELBINE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
VINORELBINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
VITAMIN A Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VITAMIN K3 Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
WARFARIN POTASSIUM Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ZAFIRLUKAST Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZIPRASIDONE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZOLEDRONIC ACID ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZOLPIDEM TARTRATE Repurposing	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALECTINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APALUTAMIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	UK £1–£4 / 28 tabs · US $5–$12 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1289494	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL12948	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2105348	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108955	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL216913	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL288441	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL477	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
GEMCITABINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GHRELIN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GIMISTOTUG	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBCASERTIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INFIGRATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INIPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
KETAMINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTROPIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHADONE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MIRVETUXIMAB SORAVTANSINE	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MORPHINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEMVALEUKIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OCIPERLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLANZAPINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLVIMULOGENE NANIVACIREPVEC	Gene therapy	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALAZESTRANT	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PAMIPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
RETIFANLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUCAPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB GOVITECAN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SITRAVATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM FERRIC GLUCONATE COMPLEX	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SURZEBICLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DERUXTECAN	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB PAMIRTECAN	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINFLUNINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MITOXANTRONE HYDROCHLORIDE	Small molecule	Phase II	Moderate	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Moderate	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABEMACICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE ACETATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ACYCLOVIR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADAVOSERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AFATINIB DIMALEATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALBENDAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALFACALCIDOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALPELISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMLODIPINE BESYLATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARIPIPRAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARSENIC TRIOXIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AUTOLOGOUS CORD BLOOD	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVDORALIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZTREONAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENMELSTOBART	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BUPARLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMONSERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	UK Varies (specialist) · US $30–$80 / 30-day (varies by product)	—	Open Targets	ChEMBL Open Targets
CAPIVASERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CARLECORTEMCEL-L	Cell therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHEMBL108358	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201192	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL136737	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108324	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CINOBUFOTALIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CITICOLINE SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COBIMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COPANLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CT-7001	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DABRAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DACOMITINIB ANHYDROUS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DAROLUTAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DATOPOTAMAB DERUXTECAN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEFACTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DISITAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DKN-01	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOSTARLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENCORAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERIBULIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETRUMADENANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EVEXOMOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EZABENLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EZURPIMTROSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FAMITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLECAINIDE ACETATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
FLUZOPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOLINIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANETESPIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEDATOLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GIMERACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLYCEROL PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GSK-2636771	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HALOPERIDOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROCODONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMIQUIMOD	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2A	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IPATASERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ITACITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVONESCIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVOSIDENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIFILEUCEL	Cell therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOBAPLATIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOPERAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORAZEPAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUNRESERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MARGETUXIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MECBOTAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MELPHALAN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MERCAPTOPURINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase II	Emerging	60	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	Open Targets	ChEMBL Open Targets
MIDOMAFETAMINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLATE MOFETIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NADROPARIN CALCIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NERATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase II	Emerging	60	UK £1–£3 / 28 tabs · US $5–$12 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
OMPENACLID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ORNIDAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OTERACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OXALIPLATIN	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
OXYCODONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OZURIFTAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PARSACLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERENOSTOBART	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENOBARBITAL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENYTOIN SODIUM	Small molecule	Phase II	Emerging	60	UK £3–£8 / supply · US $6–$15 / 30 tabs	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PIROXICAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PONATINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PROPYLTHIOURACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PSILOCYBIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RALTITREXED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REGRAMOSTIM	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RELATLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RELUGOLIX	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESINIFERATOXIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RILVEGOSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
S1?	Small molecule	Phase II	Emerging	60	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SASANLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SNX 5422	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SPARTALIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SURUFATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAFASITAMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TANESPIMYCIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TANEZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TASELISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEPOTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE UNDECANOATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINZAPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIRAGOLUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOBEMSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMADOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB REZETECAN	Biologic	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUCATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ULIXERTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UNECRITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UZATRESGENE AUTOLEUCEL	Gene therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALPROATE SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINCRISTINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
VINTAFOLIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VODUDEUTENTAN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VOLRUSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VUSOLIMOGENE ODERPAREPVEC	Gene therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZIMBERELIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHEMBL:CHEMBL1086580 Repurposing	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL3753077 Repurposing	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL91638 Repurposing	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
GSK126 Repurposing	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ICG-001 Repurposing	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
.ALPHA.-TOCOPHERYLOXYACETIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
9-AMINOCAMPTOTHECIN	Small molecule	Phase I	Emerging	35	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
A27.15	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABEXINOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE DECANOATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AEG-35156	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AG-24322	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALENDRONATE SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALINTEGIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALLANTOIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALTEPLASE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMCASERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMIFOSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMIVANTAMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMP-224	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APG-2575	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AR-67	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARGININE BUTYRATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARRY-382	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase I	Emerging	35	UK Very low cost · US Very low cost	—	Open Targets	ChEMBL Open Targets
AT-13148	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATAMPARIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATIPRIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATIRMOCICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AUMOLERTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVELUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZD-1480	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZD-7762	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZENOSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BALSTILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BANOXANTRONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BATABULIN SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BAY-1161909	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BAY-1217389	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENZOYLPHENYLUREA	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BIZELESIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BMS-387032	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BOTENSILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CABIRALIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAPTOPRIL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CARBOXYAMIDOTRIAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CASOPITANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CDX-1140	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CDX-301	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHEMBL1200810	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201439	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1643	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1683544	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHLOROGENIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHOLESTEROL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CILENGITIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CIXUTUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CMD-193	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COBOLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CPI 613	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DACARBAZINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALOTUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DAVAMOTECAN PEGADEXAMER	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DFP-13318	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DILTIAZEM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOVITINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DT-2216	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
E2.3	Small molecule	Phase I	Emerging	35	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
EC-17	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EFTOZANERMIN ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EGANELISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELACESTRANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELACESTRANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EMIBETUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENCEQUIDAR MESYLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOBLITUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPACADOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE PHOSPHATE SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETARFOLATIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
EVORPACEPT	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EXLINKIBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FGF401	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FIGITUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FISH OIL TRIGLYCERIDES	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLOXURIDINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLUCONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FORODESINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSGEMCITABINE PALABENAMIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
FOSLINANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GALLIUM MALTOLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GAMITRINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANCOTAMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GDC-0152	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEVOKIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLATIRAMER ACETATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLESATINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLPG-0187	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GOCATAMIG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GPI-0100	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HILTONOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROMORPHONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBI-188	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBI-939	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ICOTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IFINATAMAB DERUXTECAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMCNYESO	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMLUNESTRANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INEBILIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-12 HUMAN RECOMBINANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVUXOLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IXAZOMIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
KETOCONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LANCASTOTUG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LANDOGROZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROMUSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LINRODOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIRILUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LITRONESIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUCORAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUMISTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU177 EDOTREOTIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUVELTAMAB TAZEVIBULIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3007113	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3009120	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3076226	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3164530	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3200882	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MAFOSFAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHYLNALTREXONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MK-2461	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MLN-8054	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MOLGRAMOSTIM	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MUPARFOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NANATINOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NANRILKEFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NARAZACICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEGALSTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NELITOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEO-201	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIBROZETONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NT-219	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NY-ESO-1	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NZV-930	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLECLUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLINVACIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMACETAXINE MEPESUCCINATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMBIPEPIMUT-S	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONC-392	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONVANSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALIFOSFAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PARICALCITOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PATUPILONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERIFOSINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERILLYL ALCOHOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERTUZUMAB ZUVOTOLIMOD	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENYLBUTANOIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PICOPLATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PILARALISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLINABULIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
POMALIDOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
POSACONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PRADUSINSTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PRALSETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PREXASERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PX-12	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PYROXAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RABUSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RAGIFILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RALIMETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RASDEGAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RECOMBINANT HUMAN INTERLEUKIN-15	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REGN-1400	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESIQUIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RETLIRAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REZATAPOPT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIDAFOROLIMUS	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIGOSERTIB SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIMIDUCID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIVOGENLECLEUCEL	Cell therapy	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RLY-2608	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RO-5045337	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RONICICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUBITECAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUXOTEMITIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAFIMESTOMIG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SATOREOTIDE TETRAXETAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SATOREOTIDE TRIZOXETAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELITRECTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERABELISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SGX-523	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SHR-1501	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM BICARBONATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM SELENITE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM STIBOGLUCONATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOLNERSTOTUG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SONROTOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOTIGALIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SUNITINIB MALATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALADEGIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALFIRASTIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAS-106	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEMUTERKIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEPROTUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TERAMEPROCOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TERTOMOTIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TETRAXETAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEZACITABINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
THIOTEPA	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINENGOTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIPIFARNIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIVANTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIVUMECIRNON	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOSEDOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOSITUMOMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRABECTEDIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRIAPINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRICIRIBINE PHOSPHATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TSN-084	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUVUSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TYPHOID VI POLYSACCHARIDE VACCINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ULILEDLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UPROSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
URELUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UTOMILUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VADIMEZAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALSPODAR	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VATALANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VENETOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VEVOCTADEKIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VIDUTOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINBLASTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINORELBINE TARTRATE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
VORICONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VORUCICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VOSAROXIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
XL-228	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
XL-999	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZALIFRELIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZAMZETOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZANUBRUTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
Ashwagandha (Withania somnifera) OSMF review	Herbal	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Berberine OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Cannabinoids (CBD/THC) OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Curcumin OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 29 Cochrane 25 Meta-analysis 79 Trial pubs 49 RCT View evidence Registry trials NCT00689195 — Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma (UNKNOWN) PHASE1, PHASE2 NCT01048983 — Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) (WITHDRAWN) PHASE1, PHASE2 NCT07278128 — Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial (COMPLETED) PHASE2, PHASE3 NCT06281353 — The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions Tissue (COMPLETED) PHASE2, PHASE3 NCT00003365 — Sulindac and Plant Compounds in Preventing Colon Cancer (TERMINATED) NA NCT02138955 — A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (COMPLETED) PHASE1, PHASE2 NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy (RECRUITING) NA NCT06080841 — Curcumin Supplementation in Cervical Cancer (RECRUITING) NA Published literature Cochrane review Effect of curcumin intervention on radiation-induced injury: a GRADE-based systematic review and meta-analysis (BMC cancer, 2026) Cochrane review Role of curcumin and its nanoformulations in the management of oral squamous cell carcinoma: A systematic review (Dental and medical problems, 2026) Cochrane review The influence of antioxidant supplementation on adverse effects and tumor interaction during radiotherapy: a systematic review (Clinical and experimental medicine, 2025) Cochrane review The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis (Reproductive biology and endocrinology : RB&E, 2025) Cochrane review Comparative evaluation of the efficacy of herbal and benzydamine mouthwashes in preventing radiation-induced oral mucositis among head and neck cancer patients: a systematic review and network meta-analysis (Evidence-based dentistry, 2025) Meta-analysis Exploring the In Vitro Anticancer Potential of Indonesian Medicinal Plants and Natural Compounds for Breast Cancer Therapy (Asian Pacific journal of cancer prevention : APJCP, 2025) Meta-analysis Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta-Analysis, Network Pharmacology, and Mendelian Randomization (Phytotherapy research : PTR, 2025) Meta-analysis Effectiveness and mechanisms of curcumin for colorectal cancer in preclinical models:A systematic review and meta-analysis (Journal of ethnopharmacology, 2026) Systematic review Turmeric: A Comprehensive Review of Its Botany, Traditional Uses, Phytochemistry, and Mechanisms as a Functional Food (Nutrients, 2026) Systematic review Preclinical and Clinical Evidence on the Efficacy and Cytotoxicity of Curcumin and Curcumin Derivatives in Chronic Myeloid Leukemia: A Systematic Review (Phytochemical analysis : PCA, 2026) Clinical trial publication Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis (Cancer prevention research (Philadelphia, Pa.), 2026) Clinical trial publication Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial (Anticancer research, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Exercise (30 min/day) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	1 pubs View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Fermented wheat germ extract OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Green tea catechins (EGCG) OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials View evidence Registry trials NCT01317953 — Oral Green Tea Extract for Small Cell Lung Cancer (AVAILABLE) NCT01606124 — Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (TERMINATED) PHASE2 NCT00611650 — Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia (TERMINATED) PHASE2 NCT00666562 — Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer (COMPLETED) PHASE2 NCT00516243 — Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer (COMPLETED) PHASE1 NCT06015022 — EGCG for Hepatocellular Carcinoma Chemoprevention (RECRUITING) PHASE2 NCT00303823 — Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia (COMPLETED) PHASE2 NCT00573885 — Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
IV Vitamin C OSMF review	Supplement	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Ketogenic diet (Glucose management) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	3 trials View evidence Registry trials NCT05894954 — Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (COMPLETED) PHASE3 NCT05564949 — A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases (RECRUITING) NA NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer (SUSPENDED) NA CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Melatonin OSMF review	Supplement	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 24 Cochrane 30 Meta-analysis 124 Trial pubs 79 RCT View evidence Registry trials NCT06125353 — The Effect of Melatonin Supplementation on Fatigue Symptoms During Chemotherapy Treatment of Breast Cancer Patients (COMPLETED) NA NCT04251845 — Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia (UNKNOWN) NA NCT01805089 — Melatonin Versus Placebo in Breast Cancer (COMPLETED) EARLY_PHASE1 NCT00925899 — Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer (COMPLETED) PHASE2, PHASE3 NCT02506790 — Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer (UNKNOWN) PHASE2 NCT01628029 — Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00876499 — Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients (COMPLETED) NCT00625742 — Multimodal Treatment Strategy for Cancer Cachexia (TERMINATED) NA Published literature Cochrane review Melatonin in glioblastoma therapy: clinical promise and mechanistic insights from bench to bedside (Neurosurgical review, 2026) Cochrane review Pharmacological interventions for sleep disturbance ("insomnia") in patients with advanced cancer receiving specialist palliative care: a scoping review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Melatonin in cancer treatment (The Cochrane database of systematic reviews, 2025) Cochrane review Influence of melatonin supplementation on cancer-related fatigue: a meta-analysis of randomized controlled trials (Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025) Cochrane review Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials (Journal of ovarian research, 2024) Meta-analysis Exploring the potential association and experimental validation of disrupted circadian rhythms with polycystic ovary syndrome via meta-analysis and bioinformatics: a possible pathogenic mechanism (Frontiers in endocrinology, 2025) Meta-analysis Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis (JNCI cancer spectrum, 2024) Systematic review Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review (Nutrients, 2026) Systematic review The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis (Integrative cancer therapies, 2026) Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Clinical trial publication Efficacy of an exercise oncology program on sleep quality and circadian rhythm in head and neck cancer patients undergoing chemo-radiation therapy: a randomized controlled trial (PeerJ, 2026) Clinical trial publication Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study (Journal of gynecology obstetrics and human reproduction, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Mistletoe extract (Viscum album) OSMF review	Herbal	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Nigella sativa (Thymoquinone) OSMF review	Herbal	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Omega-3 fatty acids OSMF review	Supplement	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Pao Pereira OSMF review	Herbal	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Reishi mushroom OSMF review	Herbal	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Sleep optimization (7-8 hours) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Stress reduction OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 45 Cochrane 35 Meta-analysis 131 Trial pubs 117 RCT View evidence Registry trials NCT04184557 — Effectiveness of a Mindfulness Smartphone App to Reduce Emotional Distress in People With Cancer Waiting for Surgery (COMPLETED) NA NCT05469334 — DeStress for Health: Partnering With Granville and Vance Counties to Reduce Stress and Cancer Risk (Part 2) (COMPLETED) NA NCT02495376 — Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology (COMPLETED) NA NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) (NOT_YET_RECRUITING) NA NCT07229378 — Respiratory Muscle Strength Training to Prevent Respiratory Muscle Weakness in Adults Newly Diagnosed With Breast Cancer (NOT_YET_RECRUITING) NA NCT01919853 — Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response (COMPLETED) NA NCT05131490 — Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients (COMPLETED) NA NCT07470619 — Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer (COMPLETED) NA Published literature Cochrane review Comparative efficacy and safety of different acupuncture therapies for insomnia in breast cancer patients: A systematic review and Bayesian network meta-analysis (Complementary therapies in clinical practice, 2026) Cochrane review Effect of Multimodal Interventions on Pain, Stress, and Neurodevelopmental Outcomes in Neonates With Malignant and Benign Tumors: Protocol for a Systematic Review (JMIR research protocols, 2026) Cochrane review Effects of Non-Pharmacological Interventions on Psychological Distress in Patients With Malignant Tumors: A Systematic Review and Network Meta-Analysis (Worldviews on evidence-based nursing, 2025) Cochrane review Information Needs of Patients With Head and Neck Cancer and Their Supports in Relation to Treatment Management Choices: Scoping Review (JMIR cancer, 2025) Cochrane review Effects of non-pharmacological interventions on cancer-related cognitive impairment in patients with breast cancer: A systematic review and network meta-analysis (European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2025) Meta-analysis Mindfulness-Based Interventions for Depression, Anxiety, and Stress in Adults With Cancer: A Stratified Subgroup Meta-Analysis (Psycho-oncology, 2026) Meta-analysis Meta-Analysis of the Use of Chinese Martial Arts Training for Alleviating Cancer-Related Fatigue in Cancer Survivors (Cancer medicine, 2026) Meta-analysis Effectiveness of mindfulness-based interventions on quality of life in women breast cancer survivors: a systematic review and meta-analysis (Breast (Edinburgh, Scotland), 2026) Systematic review Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review (Psychiatry research, 2026) Clinical trial publication Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR[BC]) Improves Self-Reported Optimism (Psycho-oncology, 2026) Clinical trial publication Effectiveness of mindfulness-based stress reduction in managing fatigue, anxiety, and depression among non-small cell lung cancer patients receiving surgery and adjuvant chemotherapy: A randomized controlled trial (Medicine, 2026) Clinical trial publication Mindfulness-Based Stress Reduction Effects on Chemotherapy-Induced Peripheral Neuropathy Among Breast Cancer Survivors (Psycho-oncology, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Vitamin D OSMF review	Supplement	Preclinical	Emerging	30	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 111 Cochrane 279 Meta-analysis 446 Trial pubs 322 RCT View evidence Registry trials NCT04630522 — Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors (COMPLETED) PHASE1 NCT02681601 — Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer (TERMINATED) NA NCT03469271 — Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients (COMPLETED) PHASE4 NCT02936999 — Vitamin D Supplementation in Women With DCIS and/or LCIS (TERMINATED) EARLY_PHASE1 NCT00084864 — Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate (TERMINATED) PHASE2 NCT00321932 — Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant (COMPLETED) PHASE2 NCT00004928 — Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer (COMPLETED) PHASE1 NCT06642428 — Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer (RECRUITING) NA Published literature Cochrane review Association Between Serum Vitamin D Levels and Insulin Resistance in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis (The journal of obstetrics and gynaecology research, 2026) Cochrane review Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis (Frontiers in endocrinology, 2026) Cochrane review Circulating vitamin D status and prognosis in colorectal cancer: a systematic review and meta-analysis with exploratory evidence on vitamin D receptor polymorphisms (BMC cancer, 2026) Cochrane review Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026) Cochrane review A network meta-analysis of interventions for anxiety and depression in PCOS (PeerJ, 2026) Meta-analysis Risk factors of ovarian cancer: a systematic review and meta-analysis of Mendelian randomiation studies (Journal of public health (Oxford, England), 2026) Meta-analysis A Lack of Association between Vitamin D Receptor Gene Polymorphisms with Colorectal Cancer: A Comprehensive Meta-Analysis and Power Assessment (Critical reviews in eukaryotic gene expression, 2026) Systematic review The Association Between Vitamin D and Polycystic Ovary Syndrome (PCOS) in Women: A Systematic Review (Nutrients, 2026) Clinical trial publication A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer (The oncologist, 2026) Clinical trial publication Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial (Nature cancer, 2026) Clinical trial publication Effects of acupuncture on improving hormonal and metabolic biochemical characteristics in polycystic ovary syndrome (African journal of reproductive health, 2026) Clinical trial publication Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial (BMJ (Clinical research ed.), 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
(+/-)NICOTINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALFENTANIL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALLOPURINOL	Small molecule	Preclinical	Emerging	15	UK £1–£3 / 28 tabs · US $4–$10 / 30-90 tabs	—	Open Targets	ChEMBL Open Targets
AMIFAMPRIDINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANAMORELIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APREPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CEP-32496	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLODRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLONIDINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CRENOLANIB BESYLATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DESFLURANE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DICLOFENAC SODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOLASETRON MESYLATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
E-7090	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN THETA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN ZETA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERDAFITINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FENTANYL CITRATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT DIMEGLUMINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FRUQUINTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FUTIBATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLUCARPIDASE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GRANISETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GRANISETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROMORPHONE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBANDRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE HYDRATE	Small molecule	Preclinical	Emerging	15	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
KEYHOLE LIMPET HEMOCYANIN	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB SULFATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORLATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MESNA	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHADONE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METOCLOPRAMIDE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MORPHINE SULFATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NABILONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NETUPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NOREPINEPHRINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE ACETATE	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONDANSETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALONOSETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALONOSETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGILODECAKIN	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RASBURICASE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REPOTRECTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAMARIUM SM 153 LEXIDRONAM PENTASODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SYM-021	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAPENTADOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TARLATAMAB	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAS-116	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TETANUS TOXOID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TISOTUMAB VEDOTIN	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TITANIUM DIOXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMADOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TREOSULFAN	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZINC OXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Price (UK / US)	Trials & literature	Sources	Links
BEVACIZUMAB	Biologic	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 289 Cochrane 479 Meta-analysis 2345 Trial pubs 1085 RCT View evidence Registry trials NCT01492673 — Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma (COMPLETED) PHASE2 NCT00755157 — Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer (WITHDRAWN) PHASE2 NCT00952029 — Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer (COMPLETED) PHASE2, PHASE3 NCT07117877 — Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer (NOT_YET_RECRUITING) PHASE2 NCT07637851 — Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT00015951 — Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers (COMPLETED) PHASE2 NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT05476939 — Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (RECRUITING) PHASE3 Published literature Cochrane review First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety (Frontiers in immunology, 2026) Cochrane review Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis (BMC cancer, 2026) Cochrane review Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis (Brain and behavior, 2026) Cochrane review The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network Meta-Analysis of Antiangiogenic Combination Therapies (Cancer medicine, 2026) Cochrane review A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma (Asian Pacific journal of cancer prevention : APJCP, 2026) Meta-analysis Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model (Health technology assessment (Winchester, England), 2026) Meta-analysis First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression (Critical reviews in oncology/hematology, 2026) Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy (Frontiers in immunology, 2026) Clinical trial publication Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma (Technology in cancer research & treatment, 2026) Clinical trial publication Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study (Cancer communications (London, England), 2026) Clinical trial publication Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CAPECITABINE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 86 Cochrane 151 Meta-analysis 2135 Trial pubs 857 RCT View evidence Registry trials NCT00459901 — Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer (TERMINATED) PHASE2 NCT01711242 — Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma (COMPLETED) PHASE2 NCT02854072 — A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients (UNKNOWN) PHASE3 NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT02947061 — S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT07268677 — A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. (NOT_YET_RECRUITING) PHASE2 NCT03167177 — QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (WITHDRAWN) PHASE1, PHASE2 NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (NOT_YET_RECRUITING) PHASE2 Published literature Cochrane review Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis (Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2026) Cochrane review First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis (JAMA network open, 2026) Cochrane review Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis (JAMA dermatology, 2026) Cochrane review Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Cochrane review Hand-foot syndrome prevention: pharmacological interventions-systematic review and network meta-analysis (BMJ supportive & palliative care, 2026) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis (Bulletin du cancer, 2026) Systematic review Evaluating adherence to literature-derived systemic therapy standards for resectable intrahepatic cholangiocarcinoma: A systematic review and cohort study (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2026) Systematic review Tumor Lysis Syndrome in Colorectal Cancer-A Systematic Review of Literature (Journal of gastrointestinal cancer, 2026) Systematic review Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions (Endocrine, 2026) Clinical trial publication Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial (The lancet. Gastroenterology & hepatology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 29 Cochrane 39 Meta-analysis 189 Trial pubs 64 RCT View evidence Registry trials NCT06140836 — A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (ACTIVE_NOT_RECRUITING) PHASE3 NCT02074878 — CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (TERMINATED) PHASE1 NCT02568267 — Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (ACTIVE_NOT_RECRUITING) PHASE2 NCT02336451 — A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (COMPLETED) PHASE2 NCT00939770 — Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (COMPLETED) PHASE1, PHASE2 NCT03947385 — Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (RECRUITING) PHASE1, PHASE2 NCT01744652 — Dasatinib and Crizotinib in Advanced Cancer (COMPLETED) PHASE1 NCT05384626 — A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis (BMC cancer, 2026) Cochrane review Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review (BMC cancer, 2026) Cochrane review Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network (British journal of cancer, 2025) Cochrane review Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review (Expert opinion on pharmacotherapy, 2025) Cochrane review Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis (BMJ open, 2024) Meta-analysis A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer (Anticancer research, 2026) Meta-analysis Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025) Meta-analysis Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis (Future oncology (London, England), 2025) Systematic review Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review (Cells, 2026) Clinical trial publication Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan (Cancer science, 2026) Clinical trial publication Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial (Future oncology (London, England), 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DECITABINE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 11 Cochrane 28 Meta-analysis 229 Trial pubs 62 RCT View evidence Registry trials NCT01893372 — Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS) (COMPLETED) PHASE2 NCT00740181 — Decitabine, Cytarabine, GCSF for Refractory AML/MDS (TERMINATED) PHASE2 NCT02412475 — Epigenetic Reprogramming in Relapse AML (TERMINATED) PHASE1 NCT00867672 — Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia (COMPLETED) PHASE2 NCT00085293 — Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (COMPLETED) PHASE2 NCT04485052 — Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (SUSPENDED) PHASE1, PHASE2 NCT03613532 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (ACTIVE_NOT_RECRUITING) PHASE1 NCT05829226 — A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) (COMPLETED) PHASE1 Published literature Cochrane review Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm (Cancer, 2026) Cochrane review The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis (Clinical and experimental medicine, 2025) Cochrane review Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis (Medicine, 2022) Cochrane review Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis (PloS one, 2022) Cochrane review Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis (Acta oncologica (Stockholm, Sweden), 2021) Meta-analysis Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials (Annals of hematology, 2026) Meta-analysis Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis (Blood advances, 2026) Meta-analysis The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis (Annals of hematology, 2025) Meta-analysis Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes (Annals of hematology, 2025) Systematic review Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review (Annals of hematology, 2026) Clinical trial publication All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia (The New England journal of medicine, 2026) Clinical trial publication [Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia] (Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DOCETAXEL	Small molecule	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 165 Cochrane 296 Meta-analysis 4011 Trial pubs 1668 RCT View evidence Registry trials NCT03228186 — Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (TERMINATED) PHASE2 NCT00155883 — Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer (TERMINATED) PHASE2 NCT05005728 — XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (COMPLETED) PHASE2 NCT00755157 — Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer (WITHDRAWN) PHASE2 NCT02947061 — S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT03517969 — M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00073866 — Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer (COMPLETED) PHASE1, PHASE2 NCT03873272 — The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL (COMPLETED) NA Published literature Cochrane review Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making (Expert review of clinical pharmacology, 2026) Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025 (Frontiers in endocrinology, 2026) Cochrane review Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Scientific reports, 2025) Meta-analysis PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes (Cancer treatment reviews, 2026) Meta-analysis Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis (Clinical genitourinary cancer, 2026) Meta-analysis Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations (CPT: pharmacometrics & systems pharmacology, 2026) Meta-analysis Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis (Future oncology (London, England), 2026) Meta-analysis Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer (Journal of comparative effectiveness research, 2026) Systematic review Systematic review on effectiveness of flavonoids against breast cancer: insights from in-vitro, in-vivo studies and molecular pathway studies (Drug development and industrial pharmacy, 2026) Systematic review Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review (Frontiers in immunology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 17 Cochrane 24 Meta-analysis 180 Trial pubs 119 RCT View evidence Registry trials NCT05913427 — Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) (RECRUITING) PHASE2 NCT07462663 — SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer (NOT_YET_RECRUITING) PHASE4 NCT06963593 — Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy (NOT_YET_RECRUITING) PHASE4 NCT04046185 — Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer (UNKNOWN) EARLY_PHASE1 NCT03283488 — Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. (COMPLETED) PHASE2 NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer (NOT_YET_RECRUITING) PHASE2 NCT02980653 — Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT (UNKNOWN) PHASE2 NCT00002465 — High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature (The journal of nutrition, health & aging, 2024) Cochrane review Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review (Journal of gynecologic oncology, 2023) Cochrane review The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis (BJOG : an international journal of obstetrics and gynaecology, 2023) Cochrane review Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review (BioMed research international, 2022) Cochrane review Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review (Palliative medicine, 2022) Meta-analysis Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis (Journal of cachexia, sarcopenia and muscle, 2024) Meta-analysis The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials (Journal of gynecology obstetrics and human reproduction, 2021) Systematic review Pharmacological Treatments for Cancer-Related Anorexia-Cachexia Syndrome: An Umbrella Review of Systematic Reviews and Meta-Analyses (Nutrition and cancer, 2026) Clinical trial publication Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial (Gynecologic oncology, 2025) Clinical trial publication [Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study] (Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024) Clinical trial publication Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors (ESMO open, 2024) Clinical trial publication Prophylactic Versus Reactive Megestrol Acetate Use for Critical Body Weight Loss in Patients with Pharyngeal and Laryngeal Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy (Nutrition and cancer, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NIVOLUMAB	Biologic	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 187 Cochrane 357 Meta-analysis 1069 Trial pubs 431 RCT View evidence Registry trials NCT06715241 — A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS (ACTIVE_NOT_RECRUITING) PHASE2 NCT03631641 — Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy (TERMINATED) PHASE2 NCT01024231 — Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (COMPLETED) PHASE1 NCT03991130 — High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma (TERMINATED) PHASE2 NCT02538666 — An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (COMPLETED) PHASE3 NCT03371381 — An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung (TERMINATED) PHASE1, PHASE2 NCT07100405 — TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment (RECRUITING) NCT03167177 — QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (WITHDRAWN) PHASE1, PHASE2 Published literature Cochrane review Diagnosis and management of immune checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026) Cochrane review Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis (Frontiers in immunology, 2026) Cochrane review Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (Clinical lung cancer, 2026) Cochrane review First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety (Frontiers in immunology, 2026) Cochrane review Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials (BMC cancer, 2026) Meta-analysis Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis (Hematological oncology, 2026) Clinical trial publication Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma (Journal for immunotherapy of cancer, 2026) Clinical trial publication Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial (Journal for immunotherapy of cancer, 2026) Clinical trial publication CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma (Clinical lung cancer, 2026) Clinical trial publication Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study (European journal of cancer (Oxford, England : 1990), 2026) Clinical trial publication A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI) (Clinical lung cancer, 2026) Randomized controlled trial Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 (Nature, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
OLAPARIB	Small molecule	Approved	Strong	105	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 29 Cochrane 53 Meta-analysis 297 Trial pubs 141 RCT View evidence Registry trials NCT05005728 — XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (COMPLETED) PHASE2 NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT07637851 — Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT03057145 — Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT07018622 — Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (RECRUITING) PHASE2 NCT02430311 — The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. (COMPLETED) PHASE1 NCT03784014 — Molecular Profiling of Advanced Soft-tissue Sarcomas (COMPLETED) PHASE3 NCT06607692 — Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review (International journal of molecular sciences, 2025) Cochrane review Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies (European urology focus, 2026) Cochrane review PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis (JAMA network open, 2025) Cochrane review Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis (Asian Pacific journal of cancer prevention : APJCP, 2025) Cochrane review Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis (European journal of obstetrics, gynecology, and reproductive biology, 2025) Meta-analysis Effectiveness and safety of PARP inhibitors in ovarian cancer: An umbrella review of systematic reviews and meta-analyses (Critical reviews in oncology/hematology, 2025) Meta-analysis A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis (Journal of ovarian research, 2025) Meta-analysis Efficacy and safety of PARP inhibitors in prostate cancer: An umbrella review of systematic reviews and meta-analyses (Critical reviews in oncology/hematology, 2025) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib (Cancer, 2026) Clinical trial publication Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial (World journal of urology, 2026) Clinical trial publication Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial (JCO precision oncology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PACLITAXEL	Small molecule	Approved	Strong	105	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 189 Cochrane 264 Meta-analysis 5654 Trial pubs 2057 RCT View evidence Registry trials NCT06370754 — Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00019812 — Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 (COMPLETED) PHASE2 NCT01264328 — Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (COMPLETED) PHASE2 NCT00003957 — Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT06965829 — The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC (NOT_YET_RECRUITING) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA Published literature Cochrane review Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung Cancer: A Single-arm Meta-analysis (Anticancer research, 2026) Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Systematic review and first meta-analysis of the efficacy and safety of gemcitabine-cisplatin combined with paclitaxel in patients with advanced biliary tract cancer (European journal of clinical pharmacology, 2026) Cochrane review Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis (Frontiers in immunology, 2026) Cochrane review Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis (Annals of medicine, 2026) Meta-analysis Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study (Frontiers in immunology, 2026) Systematic review Dual TP53 mutations in ovarian high-grade serous carcinoma combined with squamous cell carcinoma: a case report and systematic literature review (Journal of ovarian research, 2026) Systematic review Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review (Cells, 2026) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study (Cancer communications (London, England), 2026) Clinical trial publication Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study (Signal transduction and targeted therapy, 2026) Clinical trial publication Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 16 Cochrane 18 Meta-analysis 88 Trial pubs 36 RCT View evidence Registry trials NCT03923036 — Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer (UNKNOWN) NCT04252456 — Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status (UNKNOWN) NA NCT00729157 — Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (COMPLETED) PHASE2 NCT01889680 — Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (WITHDRAWN) PHASE2 NCT04392479 — TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (UNKNOWN) PHASE3 NCT00601991 — A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia (WITHDRAWN) PHASE2 NCT06047379 — Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (RECRUITING) PHASE1, PHASE2 NCT00896662 — Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 (COMPLETED) Published literature Cochrane review Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis (Hypertension research : official journal of the Japanese Society of Hypertension, 2026) Cochrane review Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment (Annals of palliative medicine, 2024) Cochrane review Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis (Medicine, 2023) Cochrane review A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety (Critical reviews in oncology/hematology, 2023) Cochrane review Recent advances in the molecular targeted drugs for prostate cancer (International urology and nephrology, 2023) Meta-analysis Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials (Journal of clinical pharmacy and therapeutics, 2022) Meta-analysis The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis (Cancer treatment and research communications, 2021) Systematic review Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review (Molecular diagnosis & therapy, 2021) Clinical trial publication Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629) (European journal of cancer (Oxford, England : 1990), 2026) Clinical trial publication Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients (European journal of clinical investigation, 2026) Clinical trial publication A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer (International journal of clinical oncology, 2025) Clinical trial publication Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial (ESMO open, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AXITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
AZACITIDINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 8 Cochrane 6 Meta-analysis 191 Trial pubs 138 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00026377 — SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (COMPLETED) PHASE1 NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04563936 — Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (COMPLETED) PHASE3 NCT02376296 — Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients (COMPLETED) NCT02678520 — Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients (WITHDRAWN) PHASE2 NCT00349557 — Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer (COMPLETED) PHASE2 NCT02454543 — Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (ACTIVE_NOT_RECRUITING) NA Published literature Cochrane review The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis (Frontiers in endocrinology, 2023) Cochrane review Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis (JAMA network open, 2020) Cochrane review Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis (American journal of clinical oncology, 2020) Cochrane review First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials (BJU international, 2017) Cochrane review Gynecomastia in Patients with Prostate Cancer: A Systematic Review (PloS one, 2015) Meta-analysis Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials (Journal of endocrinological investigation, 2025) Meta-analysis Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma (Journal of gynecologic oncology, 2021) Systematic review Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review (ESMO open, 2024) Systematic review Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review (Journal of geriatric oncology, 2021) Clinical trial publication Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809) (The Prostate, 2026) Clinical trial publication Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy (International journal of radiation oncology, biology, physics, 2025) Clinical trial publication Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy (The Prostate, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CARFILZOMIB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CELECOXIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CERITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CETUXIMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1129	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200374	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200598	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201112	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201477	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201506	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201746	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1237054	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1455	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742992	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1742994	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1743047	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908391	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1977579	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2105737	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2216870	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL238071	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL24828	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL3137342	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL313972	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL408513	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL411	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL452231	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL488	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL513	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL691	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL705	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL717	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL727	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CLOFARABINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CYTARABINE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DENILEUKIN DIFTITOX	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 3 Cochrane 3 Meta-analysis 34 Trial pubs 4 RCT View evidence Registry trials NCT00945269 — Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (TERMINATED) PHASE1, PHASE2 NCT00493129 — Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) (COMPLETED) PHASE2 NCT00726037 — A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer (TERMINATED) PHASE2 NCT00278369 — Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer (COMPLETED) EARLY_PHASE1 NCT00003615 — Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT00880360 — A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (COMPLETED) PHASE2 NCT00051012 — Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients (COMPLETED) PHASE4 NCT00513188 — Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma (WITHDRAWN) NA Published literature Cochrane review Interventions for mycosis fungoides (The Cochrane database of systematic reviews, 2020) Cochrane review Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review (The British journal of dermatology, 2014) Cochrane review Interventions for mycosis fungoides (The Cochrane database of systematic reviews, 2012) Meta-analysis Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma (American journal of hematology, 2011) Clinical trial publication Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025) Clinical trial publication Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer (Gynecologic oncology, 2024) Clinical trial publication Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (Cancer science, 2021) Clinical trial publication Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control (Journal of immunotherapy (Hagerstown, Md. : 1997), 2019) Clinical trial publication E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study (Cancer science, 2018) Randomized controlled trial Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies (Clinical lymphoma, myeloma & leukemia, 2013) Randomized controlled trial Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Randomized controlled trial Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK) (Clinical lymphoma, 2002) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FILGRASTIM	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUDARABINE PHOSPHATE	Small molecule	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUTAMIDE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GEFITINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GOSERELIN	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
HISTRELIN	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IBRUTINIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IPILIMUMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
IXABEPILONE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 2 Cochrane 5 Meta-analysis 99 Trial pubs 33 RCT View evidence Registry trials NCT00025194 — Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer (COMPLETED) PHASE1, PHASE2 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT01079793 — Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery (WITHDRAWN) PHASE1, PHASE2 NCT00020371 — BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy (COMPLETED) PHASE1 NCT00022542 — BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma (TERMINATED) PHASE2 NCT00182702 — Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (COMPLETED) PHASE2 NCT00207090 — Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer (COMPLETED) PHASE1 NCT00789581 — A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (COMPLETED) PHASE3 Published literature Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer (Future oncology (London, England), 2010) Meta-analysis Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer (Future oncology (London, England), 2024) Meta-analysis Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis (Medicine, 2016) Meta-analysis Systematic review of ixabepilone for treating metastatic breast cancer (Breast cancer (Tokyo, Japan), 2017) Meta-analysis Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data (The Lancet. Oncology, 2007) Systematic review Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective (Clinical breast cancer, 2016) Clinical trial publication Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial (JAMA oncology, 2022) Clinical trial publication Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (British journal of cancer, 2022) Clinical trial publication A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer (Clinical breast cancer, 2021) Clinical trial publication UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer (European journal of cancer (Oxford, England : 1990), 2018) Clinical trial publication A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance) (Clinical pharmacology and therapeutics, 2019) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MITOMYCIN	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
NILUTAMIDE	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBINUTUZUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
PANITUMUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 41 Cochrane 84 Meta-analysis 275 Trial pubs 136 RCT View evidence Registry trials NCT01264328 — Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (COMPLETED) PHASE2 NCT01017653 — Panitumumab and Irinotecan for Malignant Gliomas (TERMINATED) PHASE2 NCT03231722 — First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (COMPLETED) PHASE3 NCT01130701 — A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . . (WITHDRAWN) PHASE2 NCT07543744 — A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI (RECRUITING) PHASE1 NCT05121038 — CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT01312493 — Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab (WITHDRAWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 Published literature Cochrane review Outcomes of Epidermal Growth Factor Receptor Inhibitors in Locally Advanced and Metastatic Anal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (Journal of gastrointestinal cancer, 2026) Cochrane review First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis (JAMA network open, 2026) Cochrane review The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis (European journal of pharmacology, 2025) Cochrane review Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT (PloS one, 2024) Cochrane review The Use of Fluorescent Markers to Detect and Delineate Head and Neck Cancer: A Scoping Review (Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2025) Meta-analysis Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis (Critical reviews in oncology/hematology, 2026) Meta-analysis First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group) (European journal of cancer (Oxford, England : 1990), 2026) Meta-analysis Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: A meta-analysis of survival outcomes in resectable and unresectable settings (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2026) Systematic review Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research (Clinical and translational medicine, 2026) Systematic review A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science (Cancer investigation, 2026) Clinical trial publication Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026) Clinical trial publication Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PENTOSTATIN	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
PERTUZUMAB	Biologic	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
REGORAFENIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
RITUXIMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 13 Cochrane 16 Meta-analysis 166 Trial pubs 53 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00337545 — Phase II Trial of RAD001 in Refractory Colorectal Cancer (COMPLETED) PHASE2 NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT05476939 — Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (RECRUITING) PHASE3 NCT00516412 — Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (COMPLETED) PHASE2 NCT06482086 — Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer (RECRUITING) PHASE2 NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT01334502 — Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (COMPLETED) PHASE1 Published literature Cochrane review Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (International journal of dermatology, 2026) Cochrane review [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review] (Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2025) Cochrane review mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis (Clinical transplantation, 2022) Cochrane review Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review (Journal of pediatric orthopedics. Part B, 2022) Cochrane review Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022) Meta-analysis Impact of Modern Strategies for Graft-Versus-Host Disease Prophylaxis on Relapse Risk in Matched-Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis of Randomized Trials (European journal of haematology, 2026) Meta-analysis mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis (BMJ open, 2021) Systematic review Impact of immunosuppressive therapy on non-melanoma skin cancer after solid organ transplantation: A critical systematic review (Transplant immunology, 2026) Systematic review Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates (Pediatric research, 2025) Systematic review Topical sirolimus in dermatology: a systematic review (Clinical and experimental dermatology, 2024) Clinical trial publication Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial (The Lancet. Haematology, 2026) Clinical trial publication Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS (Blood, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TEMSIROLIMUS	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
TRASTUZUMAB EMTANSINE	Biologic	Approved	Strong	100	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VISMODEGIB	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
VORINOSTAT	Small molecule	Approved	Strong	100	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALECTINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APALUTAMIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	UK £1–£4 / 28 tabs · US $5–$12 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1289494	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL12948	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2105348	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108955	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL216913	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL288441	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL477	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 37 Cochrane 76 Meta-analysis 1874 Trial pubs 923 RCT View evidence Registry trials NCT02288741 — Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (COMPLETED) PHASE3 NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL (RECRUITING) PHASE1, PHASE2 NCT05535998 — TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT (COMPLETED) NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT00966706 — Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer (COMPLETED) PHASE2 NCT01094964 — Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer (UNKNOWN) PHASE3 Published literature Cochrane review Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group (Actas urologicas espanolas, 2026) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials (PloS one, 2024) Meta-analysis The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis (Urologic oncology, 2023) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Systematic review An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis (Molecular aspects of medicine, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
GEMCITABINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
GHRELIN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GIMISTOTUG	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBCASERTIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INFIGRATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INIPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
KETAMINE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTROPIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHADONE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MIRVETUXIMAB SORAVTANSINE	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MORPHINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEMVALEUKIN ALFA	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OCIPERLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLANZAPINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLVIMULOGENE NANIVACIREPVEC	Gene therapy	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALAZESTRANT	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PAMIPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
RETIFANLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUCAPARIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB GOVITECAN	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SITRAVATINIB	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM FERRIC GLUCONATE COMPLEX	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SURZEBICLIMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DERUXTECAN	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB PAMIRTECAN	Biologic	Phase III	Moderate	80	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINFLUNINE	Small molecule	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase III	Moderate	80	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE HYDROCHLORIDE	Small molecule	Phase II	Moderate	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets, ChEMBL	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Moderate	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABEMACICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE ACETATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ACYCLOVIR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADAVOSERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AFATINIB DIMALEATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALBENDAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALFACALCIDOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALPELISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMLODIPINE BESYLATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARIPIPRAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARSENIC TRIOXIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AUTOLOGOUS CORD BLOOD	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVDORALIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZTREONAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENMELSTOBART	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BUPARLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMONSERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	UK Varies (specialist) · US $30–$80 / 30-day (varies by product)	—	Open Targets	ChEMBL Open Targets
CAPIVASERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CARLECORTEMCEL-L	Cell therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHEMBL108358	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201192	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL136737	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108324	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CINOBUFOTALIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CITICOLINE SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COBIMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COPANLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CT-7001	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CYPROHEPTADINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DABRAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DACOMITINIB ANHYDROUS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DAROLUTAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DATOPOTAMAB DERUXTECAN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEFACTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DISITAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DKN-01	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOSTARLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENCORAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERIBULIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETRUMADENANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EVEXOMOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EZABENLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EZURPIMTROSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FAMITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLECAINIDE ACETATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
FLUZOPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOLINIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANETESPIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEDATOLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GIMERACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLYCEROL PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GSK-2636771	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HALOPERIDOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROCODONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMIQUIMOD	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2A	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IPATASERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ITACITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVONESCIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVOSIDENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIFILEUCEL	Cell therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOBAPLATIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOPERAMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORAZEPAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUNRESERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MARGETUXIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MECBOTAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MELPHALAN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MERCAPTOPURINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase II	Emerging	60	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	Open Targets	ChEMBL Open Targets
MIDOMAFETAMINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MYCOPHENOLATE MOFETIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NADROPARIN CALCIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NAPROXEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NERATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase II	Emerging	60	UK £1–£3 / 28 tabs · US $5–$12 / 30–90 tabs	—	Open Targets	ChEMBL Open Targets
OMPENACLID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ORNIDAZOLE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OTERACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OXALIPLATIN	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
OXYCODONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OZURIFTAMAB VEDOTIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PARSACLISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERENOSTOBART	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENOBARBITAL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENYTOIN SODIUM	Small molecule	Phase II	Emerging	60	UK £3–£8 / supply · US $6–$15 / 30 tabs	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PIROXICAM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PONATINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PROPYLTHIOURACIL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PSILOCYBIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RALTITREXED	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REGRAMOSTIM	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RELATLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RELUGOLIX	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESINIFERATOXIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESVERATROL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RILVEGOSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
S1?	Small molecule	Phase II	Emerging	60	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SASANLIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SNX 5422	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM PHENYLBUTYRATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SPARTALIZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SURUFATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAFASITAMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TANESPIMYCIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TANEZUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TASELISIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEPOTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE UNDECANOATE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINZAPARIN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIRAGOLUMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOBEMSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMADOL	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB REZETECAN	Biologic	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUCATINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ULIXERTINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UNECRITINIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UZATRESGENE AUTOLEUCEL	Gene therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALPROATE SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINCRISTINE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase II	Emerging	60	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
VINTAFOLIDE	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VODUDEUTENTAN SODIUM	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VOLRUSTOMIG	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VUSOLIMOGENE ODERPAREPVEC	Gene therapy	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZIMBERELIMAB	Biologic	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase II	Emerging	60	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
.ALPHA.-TOCOPHERYLOXYACETIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
9-AMINOCAMPTOTHECIN	Small molecule	Phase I	Emerging	35	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
A27.15	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABEXINOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ABIRATERONE DECANOATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AEG-35156	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AG-24322	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALENDRONATE SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALINTEGIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALLANTOIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALTEPLASE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMCASERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMIFOSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMIVANTAMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AMP-224	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APG-2575	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AR-67	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARGININE BUTYRATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ARRY-382	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase I	Emerging	35	UK Very low cost · US Very low cost	—	Open Targets	ChEMBL Open Targets
AT-13148	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATAMPARIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATIPRIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ATIRMOCICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AUMOLERTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVELUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZD-1480	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZD-7762	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
AZENOSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BALSTILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BANOXANTRONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BATABULIN SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BAY-1161909	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BAY-1217389	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BENZOYLPHENYLUREA	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BIZELESIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BMS-387032	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BOTENSILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CABIRALIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CAPTOPRIL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CARBOXYAMIDOTRIAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CASOPITANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CDX-1140	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CDX-301	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHEMBL1200810	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201439	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1643	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL1683544	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHLOROGENIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CHOLESTEROL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CILENGITIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CIXUTUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CMD-193	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
COBOLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CPI 613	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DACARBAZINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DALOTUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DAVAMOTECAN PEGADEXAMER	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DFP-13318	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DILTIAZEM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOVITINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DT-2216	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
E2.3	Small molecule	Phase I	Emerging	35	Research / experimental compound — pricing not applicable for routine clinical use	—	Open Targets	ChEMBL Open Targets
EC-17	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EFTOZANERMIN ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EGANELISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELACESTRANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELACESTRANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EMIBETUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENCEQUIDAR MESYLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENOBLITUZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPACADOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE PHOSPHATE SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETARFOLATIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
EVORPACEPT	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EXLINKIBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FGF401	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FIGITUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FISH OIL TRIGLYCERIDES	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLOXURIDINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FLUCONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FORODESINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSGEMCITABINE PALABENAMIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
FOSLINANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GALLIUM MALTOLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GAMITRINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANCICLOVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GANCOTAMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GDC-0152	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GEVOKIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLATIRAMER ACETATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLESATINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLPG-0187	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GOCATAMIG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GPI-0100	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HILTONOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROMORPHONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBI-188	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBI-939	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ICOTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IFINATAMAB DERUXTECAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMCNYESO	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IMLUNESTRANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INEBILIZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-12 HUMAN RECOMBINANT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IVUXOLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IXAZOMIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
KETOCONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LANCASTOTUG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LANDOGROZUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROMUSTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LINRODOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LIRILUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LITRONESIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUCORAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUMISTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU177 EDOTREOTIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LUVELTAMAB TAZEVIBULIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3007113	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3009120	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3076226	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3164530	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LY-3200882	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MAFOSFAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHYLNALTREXONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MK-2461	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MLN-8054	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MOLGRAMOSTIM	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MUPARFOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NANATINOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NANRILKEFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NARAZACICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEGALSTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NELITOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NEO-201	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NIBROZETONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NT-219	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NY-ESO-1	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NZV-930	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLECLUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OLINVACIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMACETAXINE MEPESUCCINATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OMBIPEPIMUT-S	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONC-392	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONVANSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALIFOSFAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PARICALCITOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PATUPILONE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERIFOSINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERILLYL ALCOHOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PERTUZUMAB ZUVOTOLIMOD	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PHENYLBUTANOIC ACID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PICOPLATIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PILARALISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLERIXAFOR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PLINABULIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
POMALIDOMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
POSACONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PRADUSINSTOBART	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PRALSETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PREXASERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PX-12	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PYROXAMIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RABUSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RAGIFILIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RALIMETINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RASDEGAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RECOMBINANT HUMAN INTERLEUKIN-15	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REGN-1400	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RESIQUIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RETLIRAFUSP ALFA	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REZATAPOPT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIDAFOROLIMUS	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIFAMPIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIGOSERTIB SODIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIMIDUCID	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RIVOGENLECLEUCEL	Cell therapy	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RLY-2608	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RO-5045337	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RONICICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUBITECAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RUXOTEMITIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAFIMESTOMIG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SATOREOTIDE TETRAXETAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SATOREOTIDE TRIZOXETAN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SELITRECTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERABELISIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SGX-523	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SHR-1501	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM BICARBONATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM SELENITE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM STIBOGLUCONATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOLNERSTOTUG	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SONROTOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SOTIGALIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SUNITINIB MALATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALADEGIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TALFIRASTIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAS-106	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEMUTERKIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEPROTUMUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TERAMEPROCOL	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TERTOMOTIDE	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TETRAXETAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TEZACITABINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
THIOTEPA	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TINENGOTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIPIFARNIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIVANTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TIVUMECIRNON	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOSEDOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOSITUMOMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRABECTEDIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRIAPINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRICIRIBINE PHOSPHATE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TSN-084	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TUVUSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TYPHOID VI POLYSACCHARIDE VACCINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ULILEDLIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UPROSERTIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
URELUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
UTOMILUMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VADIMEZAN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VALSPODAR	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VATALANIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VENETOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VEVOCTADEKIN	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VIDUTOLIMOD	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINBLASTINE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VINORELBINE TARTRATE	Small molecule	Phase I	Emerging	35	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
VORICONAZOLE	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VORUCICLIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
VOSAROXIN	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
XL-228	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
XL-999	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZALIFRELIMAB	Biologic	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZAMZETOCLAX	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZANUBRUTINIB	Small molecule	Phase I	Emerging	35	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALFENTANIL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ALLOPURINOL	Small molecule	Preclinical	Emerging	15	UK £1–£3 / 28 tabs · US $4–$10 / 30-90 tabs	—	Open Targets	ChEMBL Open Targets
AMIFAMPRIDINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ANAMORELIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
APREPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CEP-32496	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLODRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CLONIDINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
CRENOLANIB BESYLATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DESFLURANE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DICLOFENAC SODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DOLASETRON MESYLATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
E-7090	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN THETA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
EPOETIN ZETA	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERDAFITINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FENTANYL CITRATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FOSAPREPITANT DIMEGLUMINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FRUQUINTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
FUTIBATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GLUCARPIDASE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GRANISETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
GRANISETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
HYDROMORPHONE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IBANDRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE HYDRATE	Small molecule	Preclinical	Emerging	15	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	Open Targets	ChEMBL Open Targets
KEYHOLE LIMPET HEMOCYANIN	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB SULFATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
LORLATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MESNA	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METHADONE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
METOCLOPRAMIDE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
MORPHINE SULFATE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NABILONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NETUPITANT	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NICOTINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
NOREPINEPHRINE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE ACETATE	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ONDANSETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALONOSETRON	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PALONOSETRON HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEGILODECAKIN	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
RASBURICASE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
REPOTRECTINIB	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SAMARIUM SM 153 LEXIDRONAM PENTASODIUM	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
SYM-021	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAPENTADOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TARLATAMAB	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TAS-116	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TETANUS TOXOID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TISOTUMAB VEDOTIN	Biologic	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TITANIUM DIOXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TRAMADOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
TREOSULFAN	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZINC OXIDE	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Preclinical	Emerging	15	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Price (UK / US)	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AFATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ALECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ASCIMINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AXITINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BICALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 8 Cochrane 6 Meta-analysis 191 Trial pubs 138 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00026377 — SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (COMPLETED) PHASE1 NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04563936 — Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (COMPLETED) PHASE3 NCT02376296 — Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients (COMPLETED) NCT02678520 — Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients (WITHDRAWN) PHASE2 NCT00349557 — Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer (COMPLETED) PHASE2 NCT02454543 — Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (ACTIVE_NOT_RECRUITING) NA Published literature Cochrane review The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis (Frontiers in endocrinology, 2023) Cochrane review Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis (JAMA network open, 2020) Cochrane review Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis (American journal of clinical oncology, 2020) Cochrane review First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials (BJU international, 2017) Cochrane review Gynecomastia in Patients with Prostate Cancer: A Systematic Review (PloS one, 2015) Meta-analysis Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials (Journal of endocrinological investigation, 2025) Meta-analysis Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma (Journal of gynecologic oncology, 2021) Systematic review Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review (ESMO open, 2024) Systematic review Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review (Journal of geriatric oncology, 2021) Clinical trial publication Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809) (The Prostate, 2026) Clinical trial publication Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy (International journal of radiation oncology, biology, physics, 2025) Clinical trial publication Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy (The Prostate, 2025) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BINIMETINIB Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BISACODYL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BITHIONOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BLINATUMOMAB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BORTEZOMIB Repurposing via AR	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
BOSUTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BRIGATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BROMOCRIPTINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
BUSULFAN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
BUTAMBEN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CABOZANTINIB S-MALATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAFFEINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCIFEDIOL ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCIPOTRIENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CALCITRIOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CANRENONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAPECITABINE Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CAPIVASERTIB Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CARBACHOL Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CARFILZOMIB Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CEFONICID SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CEFPODOXIME PROXETIL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CELECOXIB Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CEMIPLIMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CERITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CERIVASTATIN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHENODEOXYCHOLIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORDIAZEPOXIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORHEXIDINE GLUCONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORMADINONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHLOROTRIANISENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLOROXINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CHLORPROMAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHOLECALCIFEROL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CICLESONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
CLASCOTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOBETASOL PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOCORTOLONE PIVALATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CLOFARABINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CLOMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CLOTRIMAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CODEINE ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
COLCHICINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CRIZOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CROMOLYN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	UK £10–£20 / inhaler or amps · US $15–$30 / supply	—	DGIdb	ChEMBL Open Targets
CYCLANDELATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
CYPROTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
CYTARABINE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DABRAFENIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DACTINOMYCIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DANAZOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DAROLUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DAUNORUBICIN LIPOSOMAL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DECITABINE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DEFERASIROX Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DEFLAZACORT Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESERPIDINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESLANOSIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOXIMETASONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DESOXYCORTICOSTERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DESOXYCORTICOSTERONE PIVALATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DEXAMETHASONE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs	—	DGIdb	—
DIAZEPAM Repurposing via ABL1	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIDANOSINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIETHYLCARBAMAZINE CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
DIFLORASONE DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIFLUPREDNATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIGITOXIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIGOXIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DIPHENOXYLATE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DISULFIRAM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DOFETILIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
DROMOSTANOLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DRONEDARONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DROSPIRENONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DURVALUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DUTASTERIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DYCLONINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
DYDROGESTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ECONAZOLE NITRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
EFAVIRENZ Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EFLORNITHINE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENSARTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENTRECTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ENZALUTAMIDE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EPIGALLOCATECHIN GALLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EPIRUBICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	8 trials 37 Cochrane 76 Meta-analysis 1874 Trial pubs 923 RCT View evidence Registry trials NCT02288741 — Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (COMPLETED) PHASE3 NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL (RECRUITING) PHASE1, PHASE2 NCT05535998 — TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT (COMPLETED) NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT00966706 — Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer (COMPLETED) PHASE2 NCT01094964 — Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer (UNKNOWN) PHASE3 Published literature Cochrane review Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group (Actas urologicas espanolas, 2026) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials (PloS one, 2024) Meta-analysis The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis (Urologic oncology, 2023) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Systematic review An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis (Molecular aspects of medicine, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ERLOTINIB Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL 3-BENZOATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL CYPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRADIOL VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRAMUSTINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRAMUSTINE PHOSPHATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ESTRIOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ESTRONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHACRYNIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHINYL ESTRADIOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHOXZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ETHYLESTRENOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETHYNODIOL DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETONOGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ETOPOSIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
EVEROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EXEMESTANE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
EXIFONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FEBUXOSTAT Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENRETINIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FENTANYL CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FEPRAZONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FILGOTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FINASTERIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUCYTOSINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUDARABINE Repurposing via ATM	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
FLUDROCORTISONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £6–£10 / 30 tabs (0.1mg) · US $6 / 30 tabs (0.1mg, Cost Plus)	—	DGIdb	—
FLUMAZENIL Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FLUNISOLIDE ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOCINOLONE ACETONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOROMETHOLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOROURACIL Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUOXETINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
FLUOXYMESTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUPREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
FLURANDRENOLIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUSPIRILENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FLUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
FULVESTRANT Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GEFITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GEMCITABINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
GENISTEIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GENTIAN VIOLET CATION Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GESTODENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GILTERITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GLUTATHIONE DISULFIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GLYCYRRHIZIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
GRISEOFULVIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALOBETASOL PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HALOPERIDOL DECANOATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HALOPROGIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HEXACHLOROPHENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
HYDROCORTISONE BUTYRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE PROBUTATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IBRUTINIB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IBUPROFEN, SODIUM SALT Repurposing via APC	Small molecule	Approved	Strong	95	UK Very low cost OTC/prescription · US Very low cost	—	DGIdb	—
IDARUBICIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
IDEBENONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IFOSFAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IMATINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IMATINIB MESYLATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INDINAVIR SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
INDOMETHACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IOPAMIDOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IPILIMUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
ISOPROPYL UNOPROSTONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ISOTRETINOIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
IXAZOMIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LACTATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LEUPROLIDE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LIOTHYRONINE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOPERAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LORACARBEF Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
LORATADINE Repurposing via AR	Small molecule	Approved	Strong	95	UK £1–£2 / 30 tabs · US $3–$6 / 30 tabs	—	DGIdb	—
LORLATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOTEPREDNOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LOVASTATIN Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
LULICONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MAFENIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MAPROTILINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MASOPROCOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MECAMYLAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEDRYSONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEGESTROL ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MELOXICAM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MELPHALAN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEPHOBARBITAL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MEPREDNISONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	DGIdb	ChEMBL Open Targets
MESTRANOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs	—	DGIdb	ChEMBL Open Targets
METHANDROSTENOLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing via ALK	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
METHOXSALEN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
METHYLENE BLUE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
METHYLPREDNISOLONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
METHYLTESTOSTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METIPRANOLOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
METOPROLOL Repurposing via ABL1	Small molecule	Approved	Strong	95	UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MIDAZOLAM HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MIFEPRISTONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MILTEFOSINE Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MINOCYCLINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MITOMYCIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MITOTANE Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
MOCLOBEMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MOMETASONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MORICIZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
MYCOPHENOLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
MYCOPHENOLATE MOFETIL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
NANDROLONE DECANOATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NANDROLONE PHENPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NEFAZODONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NELFINAVIR Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NICARDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NICARDIPINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NICLOSAMIDE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NICOTINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NILOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NILOTINIB HYDROCHLORIDE MONOHYDRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NILUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NINTEDANIB ESYLATE Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIRAPARIB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIROGACESTAT Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NISOLDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NITAZOXANIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NITROFURAZONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NIVOLUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
NORELGESTROMIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORETHINDRONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NORETHYNODREL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
NORGESTIMATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
NORTRIPTYLINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
O-PHENANTHROLINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OCTOCRYLENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OMACETAXINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OMACETAXINE MEPESUCCINATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OSIMERTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXALIPLATIN Repurposing via ABL1	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
OXANDROLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXYMETHOLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
OXYPHENISATIN ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PACLITAXEL PROTEIN-BOUND Repurposing via AR	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
PALBOCICLIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PARAMETHASONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£4 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
PAZOPANIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PEMBROLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
PEMETREXED DISODIUM Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PENTAMIDINE ISETHIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PERHEXILINE MALEATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PERMETHRIN Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PHENELZINE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PHENFORMIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via ABL1	Small molecule	Approved	Strong	95	UK £3–£8 / supply · US $6–$15 / 30 tabs	—	ChEMBL	ChEMBL Open Targets
PIMOZIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PITAVASTATIN CALCIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PODOFILOX Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PONATINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PONATINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PRASTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PRAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PRAZOSIN Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs	—	DGIdb	—
PRAZOSIN Repurposing via ABL1	Small molecule	Approved	Strong	95	UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs	—	ChEMBL	ChEMBL Open Targets
PREDNICARBATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	—
PREDNISOLONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28 tabs · US $5–$10 / 30 tabs	—	DGIdb	ChEMBL Open Targets
PREDNISONE Repurposing via AR	Small molecule	Approved	Strong	95	UK £2–£5 / 28–30 tabs · US $4–$8 / 30 tabs	—	DGIdb	—
PRIMIDONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROBENECID Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROGESTERONE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PROMAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
PYRIDOSTIGMINE BROMIDE Repurposing via AR	Small molecule	Approved	Strong	95	UK £15–£25 / 60 tabs · US $20–$35 / 30–60 tabs	—	DGIdb	ChEMBL Open Targets
PYRIMETHAMINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PYRITHIONE ZINC Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
PYRVINIUM PAMOATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
QUININE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RABEPRAZOLE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RAMUCIRUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REGORAFENIB Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REPAGLINIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
REPOTRECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RESERPINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RESVERATROL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIBOCICLIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIFAMPIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIFAMYCIN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RIFAPENTINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
RIMONABANT Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ROCURONIUM BROMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
RUCAPARIB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SALMETEROL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SAQUINAVIR MESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SERTINDOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SERTRALINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $4–$9 / 30 tabs	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing via AR	Small molecule	Approved	Strong	95	UK £1–£3 / 28 tabs · US $4–$10 / 30–90 tabs	—	DGIdb	—
SIROLIMUS Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SIROLIMUS Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	8 trials 13 Cochrane 16 Meta-analysis 166 Trial pubs 53 RCT View evidence Registry trials NCT00943956 — Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (COMPLETED) PHASE1 NCT00337545 — Phase II Trial of RAD001 in Refractory Colorectal Cancer (COMPLETED) PHASE2 NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT05476939 — Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (RECRUITING) PHASE3 NCT00516412 — Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (COMPLETED) PHASE2 NCT06482086 — Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer (RECRUITING) PHASE2 NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT01334502 — Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (COMPLETED) PHASE1 Published literature Cochrane review Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (International journal of dermatology, 2026) Cochrane review [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review] (Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2025) Cochrane review mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis (Clinical transplantation, 2022) Cochrane review Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review (Journal of pediatric orthopedics. Part B, 2022) Cochrane review Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022) Meta-analysis Impact of Modern Strategies for Graft-Versus-Host Disease Prophylaxis on Relapse Risk in Matched-Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis of Randomized Trials (European journal of haematology, 2026) Meta-analysis mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis (BMJ open, 2021) Systematic review Impact of immunosuppressive therapy on non-melanoma skin cancer after solid organ transplantation: A critical systematic review (Transplant immunology, 2026) Systematic review Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates (Pediatric research, 2025) Systematic review Topical sirolimus in dermatology: a systematic review (Clinical and experimental dermatology, 2024) Clinical trial publication Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial (The Lancet. Haematology, 2026) Clinical trial publication Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS (Blood, 2026) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SORAFENIB Repurposing via ARID1A	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SOTALOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SPARFLOXACIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SPIRONOLACTONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
STANOZOLOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SULBACTAM Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
SULFACARBAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
SULFISOXAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
SULINDAC Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TACROLIMUS ANHYDROUS Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TALETRECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TAMOXIFEN CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TANNIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TAZOBACTAM Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TELITHROMYCIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TEMOZOLOMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TEPOTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOLACTONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE CYPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE ENANTHATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TESTOSTERONE PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
THIOGUANINE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
THIOTEPA Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TIOCONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOLVAPTAN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TOREMIFENE CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRASTUZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
TREMELIMUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIAMCINOLONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIAMCINOLONE DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRIAMTERENE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIBROMSALAN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
TRICLOSAN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIFLUOPERAZINE Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRILOSTANE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TRIPARANOL Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
TROGLITAZONE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
UMBRALISIB TOSYLATE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VALPROIC ACID Repurposing via ATM	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VALRUBICIN Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing via APC	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VEMURAFENIB Repurposing via AKT1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VENETOCLAX Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINBLASTINE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing via ABL1	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINCRISTINE SULFATE Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VINORELBINE Repurposing via APC	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	—
VINORELBINE TARTRATE Repurposing via AR	Small molecule	Approved	Strong	95	Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)	—	DGIdb	ChEMBL Open Targets
VITAMIN A Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
VITAMIN K3 Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
WARFARIN POTASSIUM Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
ZAFIRLUKAST Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZIPRASIDONE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZOLEDRONIC ACID ANHYDROUS Repurposing via ALK	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ZOLPIDEM TARTRATE Repurposing via AR	Small molecule	Approved	Strong	95	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
DARAPLADIB Repurposing via ABL1	Small molecule	Phase III	Moderate	70	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ABL1	Small molecule	Phase III	Moderate	70	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CHEMBL:CHEMBL1086580 Repurposing via APC	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL3753077 Repurposing via APC	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL91638 Repurposing via AXIN1	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	ChEMBL Open Targets
GSK126 Repurposing via ARID1A	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ICG-001 Repurposing via APC	Small molecule	Phase II	Emerging	50	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	DGIdb	—
ALPRENOLOL Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ABL1	Small molecule	Phase II	Emerging	45	Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)	—	ChEMBL	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Price (UK / US)	Trials & literature	Sources	Links
Ashwagandha (Withania somnifera) OSMF review	Herbal	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Berberine OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Cannabinoids (CBD/THC) OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Curcumin OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 29 Cochrane 25 Meta-analysis 79 Trial pubs 49 RCT View evidence Registry trials NCT00689195 — Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma (UNKNOWN) PHASE1, PHASE2 NCT01048983 — Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) (WITHDRAWN) PHASE1, PHASE2 NCT07278128 — Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial (COMPLETED) PHASE2, PHASE3 NCT06281353 — The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions Tissue (COMPLETED) PHASE2, PHASE3 NCT00003365 — Sulindac and Plant Compounds in Preventing Colon Cancer (TERMINATED) NA NCT02138955 — A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (COMPLETED) PHASE1, PHASE2 NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy (RECRUITING) NA NCT06080841 — Curcumin Supplementation in Cervical Cancer (RECRUITING) NA Published literature Cochrane review Effect of curcumin intervention on radiation-induced injury: a GRADE-based systematic review and meta-analysis (BMC cancer, 2026) Cochrane review Role of curcumin and its nanoformulations in the management of oral squamous cell carcinoma: A systematic review (Dental and medical problems, 2026) Cochrane review The influence of antioxidant supplementation on adverse effects and tumor interaction during radiotherapy: a systematic review (Clinical and experimental medicine, 2025) Cochrane review The effectiveness of nutritional supplements in improving polycystic ovary syndrome in women: a systematic review and network meta-analysis (Reproductive biology and endocrinology : RB&E, 2025) Cochrane review Comparative evaluation of the efficacy of herbal and benzydamine mouthwashes in preventing radiation-induced oral mucositis among head and neck cancer patients: a systematic review and network meta-analysis (Evidence-based dentistry, 2025) Meta-analysis Exploring the In Vitro Anticancer Potential of Indonesian Medicinal Plants and Natural Compounds for Breast Cancer Therapy (Asian Pacific journal of cancer prevention : APJCP, 2025) Meta-analysis Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta-Analysis, Network Pharmacology, and Mendelian Randomization (Phytotherapy research : PTR, 2025) Meta-analysis Effectiveness and mechanisms of curcumin for colorectal cancer in preclinical models:A systematic review and meta-analysis (Journal of ethnopharmacology, 2026) Systematic review Turmeric: A Comprehensive Review of Its Botany, Traditional Uses, Phytochemistry, and Mechanisms as a Functional Food (Nutrients, 2026) Systematic review Preclinical and Clinical Evidence on the Efficacy and Cytotoxicity of Curcumin and Curcumin Derivatives in Chronic Myeloid Leukemia: A Systematic Review (Phytochemical analysis : PCA, 2026) Clinical trial publication Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis (Cancer prevention research (Philadelphia, Pa.), 2026) Clinical trial publication Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial (Anticancer research, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Exercise (30 min/day) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	1 pubs View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Fermented wheat germ extract OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Green tea catechins (EGCG) OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials View evidence Registry trials NCT01317953 — Oral Green Tea Extract for Small Cell Lung Cancer (AVAILABLE) NCT01606124 — Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (TERMINATED) PHASE2 NCT00611650 — Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia (TERMINATED) PHASE2 NCT00666562 — Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer (COMPLETED) PHASE2 NCT00516243 — Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer (COMPLETED) PHASE1 NCT06015022 — EGCG for Hepatocellular Carcinoma Chemoprevention (RECRUITING) PHASE2 NCT00303823 — Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia (COMPLETED) PHASE2 NCT00573885 — Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
IV Vitamin C OSMF review	Supplement	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Ketogenic diet (Glucose management) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	3 trials View evidence Registry trials NCT05894954 — Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (COMPLETED) PHASE3 NCT05564949 — A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases (RECRUITING) NA NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer (SUSPENDED) NA CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Melatonin OSMF review	Supplement	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 24 Cochrane 30 Meta-analysis 124 Trial pubs 79 RCT View evidence Registry trials NCT06125353 — The Effect of Melatonin Supplementation on Fatigue Symptoms During Chemotherapy Treatment of Breast Cancer Patients (COMPLETED) NA NCT04251845 — Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia (UNKNOWN) NA NCT01805089 — Melatonin Versus Placebo in Breast Cancer (COMPLETED) EARLY_PHASE1 NCT00925899 — Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer (COMPLETED) PHASE2, PHASE3 NCT02506790 — Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer (UNKNOWN) PHASE2 NCT01628029 — Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00876499 — Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients (COMPLETED) NCT00625742 — Multimodal Treatment Strategy for Cancer Cachexia (TERMINATED) NA Published literature Cochrane review Melatonin in glioblastoma therapy: clinical promise and mechanistic insights from bench to bedside (Neurosurgical review, 2026) Cochrane review Pharmacological interventions for sleep disturbance ("insomnia") in patients with advanced cancer receiving specialist palliative care: a scoping review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Melatonin in cancer treatment (The Cochrane database of systematic reviews, 2025) Cochrane review Influence of melatonin supplementation on cancer-related fatigue: a meta-analysis of randomized controlled trials (Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025) Cochrane review Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials (Journal of ovarian research, 2024) Meta-analysis Exploring the potential association and experimental validation of disrupted circadian rhythms with polycystic ovary syndrome via meta-analysis and bioinformatics: a possible pathogenic mechanism (Frontiers in endocrinology, 2025) Meta-analysis Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis (JNCI cancer spectrum, 2024) Systematic review Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review (Nutrients, 2026) Systematic review The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis (Integrative cancer therapies, 2026) Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Clinical trial publication Efficacy of an exercise oncology program on sleep quality and circadian rhythm in head and neck cancer patients undergoing chemo-radiation therapy: a randomized controlled trial (PeerJ, 2026) Clinical trial publication Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study (Journal of gynecology obstetrics and human reproduction, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Mistletoe extract (Viscum album) OSMF review	Herbal	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Nigella sativa (Thymoquinone) OSMF review	Herbal	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Omega-3 fatty acids OSMF review	Supplement	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Pao Pereira OSMF review	Herbal	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Reishi mushroom OSMF review	Herbal	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Resveratrol OSMF review	Nutraceutical	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	OSMF Chronic Disease Review	OSMF Review Citation
Sleep optimization (7-8 hours) OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Stress reduction OSMF review	Lifestyle	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 45 Cochrane 35 Meta-analysis 131 Trial pubs 117 RCT View evidence Registry trials NCT04184557 — Effectiveness of a Mindfulness Smartphone App to Reduce Emotional Distress in People With Cancer Waiting for Surgery (COMPLETED) NA NCT05469334 — DeStress for Health: Partnering With Granville and Vance Counties to Reduce Stress and Cancer Risk (Part 2) (COMPLETED) NA NCT02495376 — Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology (COMPLETED) NA NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) (NOT_YET_RECRUITING) NA NCT07229378 — Respiratory Muscle Strength Training to Prevent Respiratory Muscle Weakness in Adults Newly Diagnosed With Breast Cancer (NOT_YET_RECRUITING) NA NCT01919853 — Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response (COMPLETED) NA NCT05131490 — Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients (COMPLETED) NA NCT07470619 — Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer (COMPLETED) NA Published literature Cochrane review Comparative efficacy and safety of different acupuncture therapies for insomnia in breast cancer patients: A systematic review and Bayesian network meta-analysis (Complementary therapies in clinical practice, 2026) Cochrane review Effect of Multimodal Interventions on Pain, Stress, and Neurodevelopmental Outcomes in Neonates With Malignant and Benign Tumors: Protocol for a Systematic Review (JMIR research protocols, 2026) Cochrane review Effects of Non-Pharmacological Interventions on Psychological Distress in Patients With Malignant Tumors: A Systematic Review and Network Meta-Analysis (Worldviews on evidence-based nursing, 2025) Cochrane review Information Needs of Patients With Head and Neck Cancer and Their Supports in Relation to Treatment Management Choices: Scoping Review (JMIR cancer, 2025) Cochrane review Effects of non-pharmacological interventions on cancer-related cognitive impairment in patients with breast cancer: A systematic review and network meta-analysis (European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2025) Meta-analysis Mindfulness-Based Interventions for Depression, Anxiety, and Stress in Adults With Cancer: A Stratified Subgroup Meta-Analysis (Psycho-oncology, 2026) Meta-analysis Meta-Analysis of the Use of Chinese Martial Arts Training for Alleviating Cancer-Related Fatigue in Cancer Survivors (Cancer medicine, 2026) Meta-analysis Effectiveness of mindfulness-based interventions on quality of life in women breast cancer survivors: a systematic review and meta-analysis (Breast (Edinburgh, Scotland), 2026) Systematic review Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review (Psychiatry research, 2026) Clinical trial publication Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR[BC]) Improves Self-Reported Optimism (Psycho-oncology, 2026) Clinical trial publication Effectiveness of mindfulness-based stress reduction in managing fatigue, anxiety, and depression among non-small cell lung cancer patients receiving surgery and adjuvant chemotherapy: A randomized controlled trial (Medicine, 2026) Clinical trial publication Mindfulness-Based Stress Reduction Effects on Chemotherapy-Induced Peripheral Neuropathy Among Breast Cancer Survivors (Psycho-oncology, 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation
Vitamin D OSMF review	Supplement	Preclinical	Emerging	30	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 111 Cochrane 279 Meta-analysis 446 Trial pubs 322 RCT View evidence Registry trials NCT04630522 — Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors (COMPLETED) PHASE1 NCT02681601 — Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer (TERMINATED) NA NCT03469271 — Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients (COMPLETED) PHASE4 NCT02936999 — Vitamin D Supplementation in Women With DCIS and/or LCIS (TERMINATED) EARLY_PHASE1 NCT00084864 — Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate (TERMINATED) PHASE2 NCT00321932 — Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant (COMPLETED) PHASE2 NCT00004928 — Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer (COMPLETED) PHASE1 NCT06642428 — Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer (RECRUITING) NA Published literature Cochrane review Association Between Serum Vitamin D Levels and Insulin Resistance in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis (The journal of obstetrics and gynaecology research, 2026) Cochrane review Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis (Frontiers in endocrinology, 2026) Cochrane review Circulating vitamin D status and prognosis in colorectal cancer: a systematic review and meta-analysis with exploratory evidence on vitamin D receptor polymorphisms (BMC cancer, 2026) Cochrane review Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026) Cochrane review A network meta-analysis of interventions for anxiety and depression in PCOS (PeerJ, 2026) Meta-analysis Risk factors of ovarian cancer: a systematic review and meta-analysis of Mendelian randomiation studies (Journal of public health (Oxford, England), 2026) Meta-analysis A Lack of Association between Vitamin D Receptor Gene Polymorphisms with Colorectal Cancer: A Comprehensive Meta-Analysis and Power Assessment (Critical reviews in eukaryotic gene expression, 2026) Systematic review The Association Between Vitamin D and Polycystic Ovary Syndrome (PCOS) in Women: A Systematic Review (Nutrients, 2026) Clinical trial publication A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer (The oncologist, 2026) Clinical trial publication Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial (Nature cancer, 2026) Clinical trial publication Effects of acupuncture on improving hormonal and metabolic biochemical characteristics in polycystic ovary syndrome (African journal of reproductive health, 2026) Clinical trial publication Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial (BMJ (Clinical research ed.), 2026) CT.gov search · Cochrane · PubMed	OSMF Chronic Disease Review	OSMF Review Citation

Natural Products

54 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Price (UK / US)	Trials & literature	Sources	Links
Omega-3 Fatty Acids Natural product Cochrane review Comparison of EPA and DHA&EPA on body weight, BMI, and lean body mass i… Cochrane review Impacts of omega-3 fatty acids intervention on immune functions and cli… Cochrane review Perioperative Immunonutrition in Gastrointestinal Oncology: A Comprehen…	Nutraceutical	Approved	Emerging	19	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 26 Cochrane 31 Meta-analysis 149 Trial pubs 129 RCT View evidence Registry trials NCT02352779 — Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors (COMPLETED) NA NCT01849250 — Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors (COMPLETED) PHASE2 NCT01831310 — Nutrition for Colorectal Cancer Patients and Neutrophil Functions (COMPLETED) PHASE4 NCT03169777 — QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (WITHDRAWN) PHASE1, PHASE2 NCT06128798 — Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. (UNKNOWN) NA NCT00723398 — Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention (COMPLETED) NA NCT01819961 — Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery (UNKNOWN) PHASE4 NCT02278965 — Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer (COMPLETED) PHASE1 Published literature Cochrane review Comparison of EPA and DHA&EPA on body weight, BMI, and lean body mass in cancer patients: a network meta-analysis (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis (BMC cancer, 2025) Cochrane review Perioperative Immunonutrition in Gastrointestinal Oncology: A Comprehensive Umbrella Review and Meta-Analysis on Behalf of TROGSS-The Robotic Global Surgical Society (Nutrients, 2025) Cochrane review Effects of Omega-3 Fatty Acids on Oral Mucositis Induced by Anticancer Therapy: A Meta-Analysis (Nutrition and cancer, 2025) Cochrane review Effect of perioperative immunonutrition on outcomes in gastric cancer surgery patients: A systematic review and evidence map (Clinical nutrition ESPEN, 2025) Meta-analysis Omega-3 Fatty Acids Increase Weight and Quality of Life Scores in Patients With Advanced Non-Small Cell Lung Cancer and Cancer Cachexia: A Meta-Analysis (Integrative cancer therapies, 2024) Systematic review Pharmacological Treatments for Cancer-Related Anorexia-Cachexia Syndrome: An Umbrella Review of Systematic Reviews and Meta-Analyses (Nutrition and cancer, 2026) Systematic review The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis (Integrative cancer therapies, 2026) Clinical trial publication Effect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial (Nutrients, 2026) Clinical trial publication The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial (The Journal of nutritional biochemistry, 2025) Clinical trial publication Flaxseed intervention and reproductive endocrine profiles in patients with polycystic ovary syndrome: an open-labeled randomized controlled clinical trial (Frontiers in endocrinology, 2025) Clinical trial publication The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial (Nutrients, 2024) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Probiotics Natural product Cochrane review Gut microbiota modulation as an adjuvant therapy to improve treatment r… Cochrane review Gut microbiota, a new approach to management of polycystic ovary syndro… Cochrane review Comparing various bowel preparation regimens in constipated patients un…	Probiotic	Approved	Emerging	16	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 68 Cochrane 70 Meta-analysis 99 Trial pubs View evidence Registry trials NCT03642548 — Probiotics Combined With Chemotherapy for Patients With Advanced NSCLC (UNKNOWN) PHASE3 NCT05122546 — CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (ACTIVE_NOT_RECRUITING) PHASE1 NCT03325023 — Effect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome Patients (UNKNOWN) PHASE4 NCT03870607 — Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) (UNKNOWN) PHASE2 NCT01706393 — Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx) (UNKNOWN) NA NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT06865521 — Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer (ACTIVE_NOT_RECRUITING) NA NCT00197873 — Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea (COMPLETED) NA Published literature Cochrane review Gut microbiota modulation as an adjuvant therapy to improve treatment response and survival in brain tumor patients: a systematic review (Neurosurgical review, 2026) Cochrane review Gut microbiota, a new approach to management of polycystic ovary syndrome: a systematic review, meta-analysis and meta-evidence of 26 randomized controlled trials (Journal of ovarian research, 2026) Cochrane review Comparing various bowel preparation regimens in constipated patients undergoing colonoscopy: A systematic review and network meta-analysis of randomised controlled trials (Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026) Cochrane review A network meta-analysis of interventions for anxiety and depression in PCOS (PeerJ, 2026) Cochrane review Interventions Targeting the Gut Microbiome to Improve Cancer Treatment Outcomes and Their Gastrointestinal Side Effects: A Systematic Review and Meta-analysis (The Journal of nutrition, 2026) Meta-analysis Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis (Frontiers in endocrinology, 2026) Meta-analysis Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): A systematic review and meta-analysis (Scientific reports, 2026) Systematic review Anticancer Potential of Lacticaseibacillus rhamnosus in Colorectal Cancer-A Systematic Review of In Vitro Cell Culture Evidence (International journal of molecular sciences, 2026) Systematic review Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review (World journal of urology, 2026) Clinical trial publication Bowel Stimulation Before Loop Ileostomy Closure Using Probiotics: Study Protocol for a Randomized Controlled Trial at a Single Center (JMIR research protocols, 2026) Clinical trial publication Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial (Journal of gastrointestinal cancer, 2026) Clinical trial publication A randomized controlled trial of probiotics to reduce the severity of oral mucositis in patients with oropharyngeal carcinoma undergoing concurrent chemoradiotherapy (Journal of cancer research and therapeutics, 2026) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
Melatonin Natural product Cochrane review Melatonin in glioblastoma therapy: clinical promise and mechanistic ins… Cochrane review Pharmacological interventions for sleep disturbance ("insomnia") in pat… Cochrane review Melatonin in cancer treatment	Nutraceutical	Phase III	Emerging	16	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 24 Cochrane 30 Meta-analysis 124 Trial pubs 79 RCT View evidence Registry trials NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT04364347 — Chemotherapy-induced Circadian Rhythm Disruption (UNKNOWN) NCT00506064 — Melatonin Postoperative Sleep Study in Breast Cancer Patients (TERMINATED) PHASE1 NCT06696378 — Melatonin Supplementation and Exercise Program in Breast Cancer Women (RECRUITING) NA NCT01355523 — The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients (TERMINATED) PHASE2, PHASE3 NCT02454855 — Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (TERMINATED) PHASE3 NCT02630004 — Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation (COMPLETED) PHASE1, PHASE2 Published literature Cochrane review Melatonin in glioblastoma therapy: clinical promise and mechanistic insights from bench to bedside (Neurosurgical review, 2026) Cochrane review Pharmacological interventions for sleep disturbance ("insomnia") in patients with advanced cancer receiving specialist palliative care: a scoping review (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025) Cochrane review Melatonin in cancer treatment (The Cochrane database of systematic reviews, 2025) Cochrane review Influence of melatonin supplementation on cancer-related fatigue: a meta-analysis of randomized controlled trials (Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025) Cochrane review Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials (Journal of ovarian research, 2024) Meta-analysis Exploring the potential association and experimental validation of disrupted circadian rhythms with polycystic ovary syndrome via meta-analysis and bioinformatics: a possible pathogenic mechanism (Frontiers in endocrinology, 2025) Meta-analysis Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis (JNCI cancer spectrum, 2024) Systematic review Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review (Nutrients, 2026) Systematic review The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis (Integrative cancer therapies, 2026) Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Clinical trial publication Efficacy of an exercise oncology program on sleep quality and circadian rhythm in head and neck cancer patients undergoing chemo-radiation therapy: a randomized controlled trial (PeerJ, 2026) Clinical trial publication Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study (Journal of gynecology obstetrics and human reproduction, 2026) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Selenium Natural product Meta-analysis Systematic Review and Meta-Analysis: Association Between Circulating an… Meta-analysis The association between micronutrient status and clinical outcomes in c… Meta-analysis Low level of selenium predicts high incidence of colorectal cancer	Nutraceutical	Approved	Emerging	16	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 71 Meta-analysis 231 Trial pubs 170 RCT View evidence Registry trials NCT04670393 — Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF (COMPLETED) NA NCT00112892 — Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT00006392 — S0000 Selenium and Vitamin E in Preventing Prostate Cancer (COMPLETED) PHASE3 NCT04683575 — Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma (UNKNOWN) PHASE4 NCT00022165 — Selenium in the Prevention of Cancer (COMPLETED) NA NCT03673995 — Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS (COMPLETED) NA NCT00736164 — Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer (WITHDRAWN) PHASE2 NCT07341217 — Chemo Brain Prehab Project (NOT_YET_RECRUITING) NA Published literature Meta-analysis Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk (The breast journal, 2026) Meta-analysis The association between micronutrient status and clinical outcomes in children with cancer undergoing treatment: A systematic review and meta-analysis (Clinical nutrition (Edinburgh, Scotland), 2026) Meta-analysis Low level of selenium predicts high incidence of colorectal cancer (BMC public health, 2026) Meta-analysis Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials (BMC endocrine disorders, 2026) Meta-analysis The Association Between Selenium Levels and Risk of Prostate Cancer: A Systematic Review and Meta-analysis of 16,964 Participants (1980-2024) (Asian Pacific journal of cancer prevention : APJCP, 2025) Systematic review Air Pollution and Brain Tumors in Children. A Systematic Review (Current environmental health reports, 2026) Systematic review HEAVY METAL TOXICITY VERSUS TRACE ELEMENT PROTECTION IN WOMEN'S REPRODUCTIVE HEALTH - A SYSTEMATIC REVIEW (Georgian medical news, 2025) Clinical trial publication Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial (Anticancer research, 2026) Clinical trial publication Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study (BMC medicine, 2026) Clinical trial publication Plasma proteomic profiles reveal immune modulation by immunonutrition in GI cancer (Nutrition (Burbank, Los Angeles County, Calif.), 2026) Clinical trial publication Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication Effects of postoperative antioxidants on the salivary glands in patients with thyroid cancer undergoing radioactive iodine-131 treatment (Nuclear medicine communications, 2024) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Alpha-Lipoic Acid Natural product Alpha-lipoic acid as a preventive measure in radiation-induced oral muc… PREVENTION OF PACLITAXEL-INDUCED MOTOR NEUROPATHY OF FIBULAR AND TIBIAL… Randomized controlled trial of bromelain and alpha-lipoic acid in breas…	Nutraceutical	Approved	Emerging	7	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 2 Cochrane View evidence Registry trials NCT05231980 — Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate (COMPLETED) PHASE2 NCT02232152 — CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (COMPLETED) PHASE1 NCT07256119 — Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients (RECRUITING) NA NCT01839981 — CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (COMPLETED) PHASE1 NCT05733000 — CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors (RECRUITING) PHASE2 NCT06406127 — Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients (UNKNOWN) PHASE4 NCT00477607 — Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin (COMPLETED) PHASE2, PHASE3 NCT07574684 — Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC (NOT_YET_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed		PubChem
Boswellia Natural product Randomized controlled trial of bromelain and alpha-lipoic acid in breas… Chemoprevention Agents to Reduce Mammographic Breast Density in Premeno… Anti-inflammatory and anti-cancer activities of frankincense: Targets,…	Botanical	Approved	Emerging	7	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	6 trials 11 Trial pubs View evidence Registry trials NCT06590077 — Impact of Aromatherapy on Wellbeing and Relaxation in Gynae Oncology Patients Post Treatment (ENROLLING_BY_INVITATION) NA NCT06119438 — Aromatherapy on Pain and Anxiety of the Patients Undergoing Prostate Biopsy (COMPLETED) NA NCT00243022 — Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme (TERMINATED) PHASE2 NCT04669119 — Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy. (UNKNOWN) PHASE4 NCT03149081 — A "Window Trial" on Boswellia for Breast Cancer Primary Tumors (COMPLETED) PHASE1 NCT04161833 — Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) (COMPLETED) NA CT.gov search · Cochrane · PubMed		PubChem
L-Carnitine Natural product Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life… Systematic review Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for In… Systematic review Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Revi…	Amino acid	Approved	Emerging	7	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 31 RCT View evidence Registry trials NCT07266259 — Effect of Levocarnitine Plus Myoinositol Versus Myoinositol Alone on Hormonal and Insulin Resistance in PCOS Women (RECRUITING) NA NCT06233890 — The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (UNKNOWN) NCT00775645 — S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo (COMPLETED) PHASE3 NCT01379976 — Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer (TERMINATED) PHASE3 NCT01665547 — Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome (UNKNOWN) PHASE4 NCT03630341 — Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome (COMPLETED) PHASE4 NCT00247975 — Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy (TERMINATED) PHASE2, PHASE3 NCT01526564 — Clinical Study on Acetyl-L-Carnitine (COMPLETED) PHASE3 Published literature Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Systematic review Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024) Systematic review Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review (International journal of molecular sciences, 2024) Systematic review Effects of L-carnitine supplementation for women with polycystic ovary syndrome: a systematic review and meta-analysis (PeerJ, 2022) Systematic review Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review (Medicina (Kaunas, Lithuania), 2022) CT.gov search · Cochrane · PubMed		PubChem
Cordyceps Natural product Clinical trial publication Cordyceps militaris Enhances Cell-Mediated Immunity in Healthy Korean M… Clinical trial publication [Effect of Jinshuibao capsule on the immunological function of 36 patie…	Mushroom	Phase III	Emerging	7	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	5 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT06598033 — Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer (RECRUITING) PHASE2, PHASE3 NCT06601283 — Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer (RECRUITING) PHASE2, PHASE3 NCT03479294 — Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection (TERMINATED) NCT04821258 — Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery for Colorectal Cancer (UNKNOWN) NA NCT03745261 — Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD (UNKNOWN) PHASE3 Published literature Clinical trial publication Cordyceps militaris Enhances Cell-Mediated Immunity in Healthy Korean Men (Journal of medicinal food, 2015) Clinical trial publication [Effect of Jinshuibao capsule on the immunological function of 36 patients with advanced cancer] (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1995) CT.gov search · Cochrane · PubMed		—
Curcumin Natural product In Vitro Study Synergistic effect of curcumin and adriamycin on apoptosis in retinal t… Review Therapeutic potential of curcumin in major retinal pathologies.	Food compound	Phase III	Emerging	7	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	8 trials 49 RCT View evidence Registry trials NCT00295035 — Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer (UNKNOWN) PHASE3 NCT00969085 — Trial of Curcumin in Cutaneous T-cell Lymphoma Patients (WITHDRAWN) PHASE2 NCT04208334 — The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer (COMPLETED) PHASE2 NCT04731844 — Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer (COMPLETED) PHASE2 NCT06044142 — Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment (COMPLETED) PHASE1 NCT01917890 — Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer (COMPLETED) NA NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy (RECRUITING) NA NCT02138955 — A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (COMPLETED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed		PubChem
Genistein Natural product A Systematic Review of Food-Derived DNA Methyltransferase Modulators: M… Mechanism of action of genistein on breast cancer and differential effe… A Systematic Review and Meta-Analysis of the Effects of Dietary Isoflav…	Food compound	Phase II	Emerging	6	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	2 trials View evidence Registry trials NCT02567799 — BIO 300 Non-Small Cell Lung Cancer Study (COMPLETED) PHASE1, PHASE2 NCT02624388 — Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Imatinib Natural product Impact of clinical response and treatment tolerability on HRQoL in newl… Evaluating the use of rodents as in vitro, in vivo and ex vivo experime… Patient-reported outcomes in Philadelphia chromosome-positive acute lym…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Erlotinib Natural product Integrating Metronomic Therapy With Standard Chemotherapy in Advanced U… Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignanci… Hepatotoxicity and efficacy associated with first- and new-generation E…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
9-benzyl-9h-adenine Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
7H-adenine Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Alvocidib Natural product Integrin-binding sialoprotein as an extracellular matrix-associated ind… Use of Small-Molecule Inhibitors of CILK1 and AURKA as Cilia-Promoting… A pan-cancer analysis reveals the oncogenic and immunological role of i…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Pazopanib Natural product Case Report: donor cell-derived leukemia after allogeneic stem cell tra… Integrated Stress Response and Necroptosis Drive Epithelial Dysfunction… Targeting mitochondrial metabolism in renal cell carcinoma with melaton…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Midostaurin Natural product Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin… Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mu…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Seliciclib Natural product Lead Discovery via Scaffold Refinement: Structure-Guided Optimization o… The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti… (R)-6-[N-(3-(4-chlorophenyl) propyl] derivative of (R)-roscovitine inhi…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporine Natural product FLIM Characterization of Staurosporine-Induced Changes in Endogenous Ce… Design, synthesis, and antiproliferative activity of novel thiazole-bas… Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular St…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Semaxanib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Medroxyprogesterone Acetate Natural product Long-term hormone therapy for perimenopausal and postmenopausal women Efficacy of drugs treatment in patients with endometrial hyperplasia wi… Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Te…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Progesterone Natural product Genomic landscape of triple-negative breast cancer in South Asian popul… Immune checkpoint inhibitors and chemotherapy versus chemotherapy for e… From tumor microenvironment orchestrators to actionable targets: a syst…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Prednisolone Natural product Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients Wi… Detection of Homologous Recombination Repair Gene Mutations by Tumor Ti… Saruparib in combination with androgen receptor pathway inhibitors in m…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Stanolone Natural product Stanolone-1,2,3-Triazole derivatives: Synthesis, DNA damage in tumor ce… Chemical compounds that suppress hypoxia-induced stress granule formati… Sensitivity of luteinizing hormone and gonadal steroid responses to sin…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Mifepristone Natural product A randomized phase II trial of nab-paclitaxel with or without mifeprist… Transcriptomic Profile of Breast Tissue of Premenopausal Women Followin… Antiprogestins reduce epigenetic field cancerization in breast tissue o…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Thiourea Natural product Hybridization of isatin and benzoxazolinone via a diethyl spacer: a new… A naphthyl polymer with STING-activating property for antigen and adjuv… Synthesis and Biological Activity of Guanidine Scaffold: A Comprehensiv…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Dactolisib Natural product Establishment and validation of a prognostic model for pancreatic cance… Integrated analysis of programmed cell death-related genes identifies C… Intrinsic resistance to RAS inhibitors is driven by dysregulation of KR…	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Tak-901 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Nintedanib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Tivozanib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Tak-593 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Saracatinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Danusertib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Axitinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Tg100-801 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Adavosertib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
At-9283 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Lenvatinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Aee-788 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Masitinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Ibrutinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Pf-03758309 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Acalabrutinib Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
Sb590885 Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ChEMBL	ChEMBL PubChem ChEMBL
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ClinicalTrials.gov	PubChem
2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]chroman-6-ol Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—	ClinicalTrials.gov	PubChem
7-Keto Dhea Natural product	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—
Beta Sitosterol Natural product	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—
Bilberry Natural product	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—
Copper Natural product	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—
D-Ribose Natural product	Food compound	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		PubChem
Epimedium Natural product	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—
Oridonin Natural product In Vitro Study Oridonin displays potent anticancer effect against uveal melanoma cells…	Nutraceutical	Preclinical	Emerging	0	Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)	—		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.